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This is the first report from the European Centre for Disease 
Prevention and Control (ECDC) on the enhanced surveillance 
of hepatitis B and C viral infections. It aims to describe basic 
trends and epidemiological features of both diseases across 
countries in the European Union and European Economic 
Area (EU/EEA) for the years 2006 to 2011. Enhanced surveil-
lance of hepatitis B and C in Europe provides important 
information to help monitor the distribution of the diseases 
and to evaluate the public health response to control the 
transmission of infections. 
Data were collected on a range of demographic and 
specific epidemiological variables for both infections. 
Data completeness varied considerably across variables 
and countries, and a small proportion of countries were 
not able to provide data as defined by the new EU 2012 
case definitions1. Nevertheless, this f irst data collec-
tion is an important step towards the harmonisation of 
hepatitis B and C surveillance across countries to enable 
a better understanding of the distribution of these infec-
tions across Europe.
The data collected, using the new EU 2012 case definition 
for hepatitis B, includes both acute and chronic infections. 
Previous EU case definitions defined only acute cases, and 
still in many countries, only acute hepatitis B is notifiable 
nationally. 
In 2011, 17 025 cases of hepatitis B were reported from 28 
EU/EEA Member States; 2 812 (16.5%) of these cases were 
reported as acute, 11 557 (67.9%) of cases were chronic and 
2 312 (13.6%) were classified as ‘unknown’. Rates in acute cases 
declined over time which is likely to be related to vaccina-
tion programmes. Rates of chronic infection varied widely 
between countries and aside from differences in surveillance 
systems they are most likely attributed to differential levels 
of screening and diagnostic testing. Hepatitis B was more 
often reported in men than women, with an overall rate of 
4.1 cases per 100 000 for men and 2.7 for women. The most 
affected age group were those between 25 and 34 years old, 
accounting for 32.9% of cases, followed by those younger 
than 25 years (16.7%).
For hepatitis B, there was a striking difference between 
reported modes of transmission by disease status. For acute 
infection, heterosexual transmission and nosocomial transmis-
sion were the most commonly reported routes of transmission. 
For chronic infections, mother-to-child transmission was the 
most common reported transmission route, most likely due 
to a high proportion of ‘imported’ cases. 
In terms of absolute numbers, hepatitis C represents a greater 
disease burden than hepatitis B. 
1 Decision No 2012/506/EU: Commission Implementing Decision of 
8 August 2012 amending Decision 2002/253/EC laying down case 
definitions for reporting communicable diseases to the Community 
network under Decision No 2119/98/EC of the European Parliament 
and of the Council (notified under document C(2012) 5538)
In 2011, 29 896 cases of hepatitis C were reported from 26 EU/
EEA Member States, representing an overall notification rate 
of 7.8 cases per 100 000 population. Of these cases, 398 cases 
(1.3%) were reported as ‘acute’, 2 913 (9.7%) as ‘chronic’ and 
24 337 (81.4%) as ‘unknown’. Although some countries only 
report acute viral hepatitis C cases, the majority of reported 
cases were classified as chronic or ‘unknown’. In countries 
able to report all viral hepatitis C cases, it is likely that most of 
these ‘unknown’ cases are chronic cases as acute hepatitis C 
is difficult to diagnose clinically or serologically. There was 
marked variation between countries in the reported cases 
of acute, chronic or ‘unknown’ hepatitis C. This variation is 
related to several factors including differences in surveillance 
systems as well as variations in national screening and testing 
practices across countries. 
The most affected age group for the reported hepatitis C 
cases were those between 25 and 34 years old which 
account for 28.2% of the total number of cases in 2011. 
There were more male cases reported than female cases 
resulting in a male-to-female rate ratio of 2:1. Injecting drug 
use was the most commonly reported route of transmission. 
The enhanced surveillance of hepatitis  B and  C across 
Europe has highlighted the significant burden of these 
infections as well as considerable differences in the epide-
miology of these infections. The comparability of data 
across countries is impaired by differences in surveillance 
systems. Improvements in the quality and completeness 
of the data over time will further improve the usefulness 
of the data. 
Summary
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ECDC started to coordinate the enhanced surveillance for 
hepatitis  B and  C in 2011. The Centre strives to attain a 
high quality of standardised hepatitis surveillance data 
from the 30 countries of the European Union (EU) and the 
European Economic Area (EEA). Surveillance at the EU level 
is facilitated by the European Surveillance System (TESSy), 
a web-based system which is designed to offer Member 
States a single entry point for data submission and retrieval 
for all communicable diseases under EU surveillance, 
including hepatitis  B and  C infections. Member States 
are expected to submit data related to all variables in the 
dataset, if available and relevant, as stipulated by Decision 
2119/98/EC of the European Commission. The collection 
of data through TESSy helps in tackling the heterogeneity 
in surveillance systems across Member States by making 
surveillance data comparable so that they can be shared 
and analysed across Europe in a meaningful way.
A report on surveillance systems and hepatitis  B virus 
(HBV) and hepatitis C virus (HCV) prevention programmes 
revealed that surveillance systems for HBV and HCV exist 
in all EU/EEA countries, but there are great differences 
between these systems in terms of what data is collected 
and how this is undertaken[1]. These results confirmed the 
findings of a previous survey of the published literature 
which found marked variation in the case definitions in use, 
and an inability for many countries to distinguish between 
acute and chronic cases of HBV and HCV [2].
The aim of enhanced surveillance is to improve the epide-
miological understanding of acute and chronic hepatitis 
infections across the EU. The enhanced surveillance 
programme for hepatitis  B and  C includes revised case 
definitions for both infections (see Annex 1). For hepa-
titis B, the case definition includes both acute and chronic 
cases and a greater range of serological tests. For hepa-
titis C, the revised case definition excludes any resolved 
cases and includes new serological test for hepatitis  C 
antigen (HCV core). These revised (and broadened) case 
definitions provide greater flexibility and inclusivity for 
capturing cases. The differentiation between acute and 
chronic infections, which is essential for understanding 
the epidemiology, is implemented through the StageHEP 
variable (see Annex 2).
This ECDC surveillance report on hepatitis B and C covers 
the years 2006 to 2011 and aims to describe basic trends 
and epidemiological features of these two diseases. The 
data are presented in two disease-specific chapters. 
1. Introduction
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2.1. Reporting in the European 
Surveillance System for 
hepatitis B and C surveillance
In the EU/EEA countries, the nominated national contact 
points for hepatitis B and C surveillance report data by 
direct upload into TESSy. A set of automated validation rules 
verifies the data during upload to improve data quality. 
Two types of data can be submitted for both hepatitis B 
and  C: case-based and aggregated data. The European 
Surveillance System aims to include case-based reports 
for each disease, but aggregated data will also be accepted 
until all Member States are in a position to comply with 
the EU standard of case-based reporting. 
The hepatitis B and C dataset consists of the common vari-
able dataset for reporting all diseases, combined with an 
enhanced dataset specific to hepatitis B and C. The two 
enhanced datasets differ slightly from each other, with 
32 variables recommended for the reporting of hepatitis B 
and 30 variables for hepatitis C (annex 3). 
2.2. Implementation of EU case 
definitions
Countries are formally requested to follow the new EU (EU 
2012) case definitions for hepatitis B and C for reporting to 
the European level2. These case definitions are provided 
in Annex 1. 
It is recognised, however, that the case definitions for 
hepatitis  B and  C as currently applied in a number of 
countries differ from these new case definitions. Data 
using different case definitions will still be accepted in 
the system until countries are in a position to conform to 
the new EU case definitions. It is requested that all case 
definitions used by countries are specified in the data 
source when uploading data into TESSy. 
2.3. Data collection 2006–2011
In 2011, surveillance data on hepatitis B and C were collected 
for the first time in TESSy. The 2006–2010 data submission 
for both hepatitis B and C surveillance took place between 
15 December 2011 and 15 February 2012. A second data 
collection took place between 9 September and 19 October 
2012 to collect 2011 data. The data presented in this report 
were retrieved from the database on 19 November 2012. 
For the period 2006–2011, data were collected in case-
based format as described in the hepatitis B and C reporting 
2 2012/506/EU: Commission Implementing Decision of 8 August 
2012 amending Decision 2002/253/EC laying down case definitions 
for reporting communicable diseases to the Community network 
under Decision No 2119/98/EC of the European Parliament and of 
the Council (notified under document C(2012) 5538) Text with EEA 
relevance
protocol. If case-based data were not available, the aggre-
gate format was accepted.
To specify the national surveillance system from which 
the reported data originate, the variable ‘data source’ is 
included as a compulsory part of reporting. International 
comparisons are hampered by differences in surveillance 
systems because the quality of national surveillance varies. 
Interpretation and cross-country comparisons should be 
made with caution as the amount of under-diagnosis and 
under-reporting varies across countries. The source of 
data is described in each disease-specific chapter and 
provides an overview of the heterogeneity in reporting 
systems across countries. 
2.4. Data analysis 
An analysis of the completeness of data and ‘Data source’ 
variable provides an overview by country of the avail-
ability and origin of data. This information is needed to 
help interpret the actual data reported. It has to be taken 
into account that several countries made changes to their 
surveillance systems during the reporting period. In some 
cases, historical data were not included as they would not 
have been comparable with the subsequent enhanced data. 
Hepatitis B and C data are presented by ‘Date of Diagnosis’ 
and if not available, by ‘Date of Statistics’ as outlined 
in the hepatitis B and C reporting protocol. The date of 
diagnosis will be used for the analysis and the report. 
When comparing the different dates across the database, 
there were only minor differences between them in a few 
of the countries.
Annual rates are calculated per 100 000 population for 
countries that have comprehensive surveillance systems. 
Country population denominators used to calculate rates 
are based on data from the Eurostat database3.
In the case of hepatitis B infections in the UK, population 
data from the Office for National Statistics (ONS) were 
used in order to exclude the country of Scotland which was 
unable to provide any hepatitis B data. Mid-2008 adjusted 
ONS population estimates were used across all years for 
the calculation of rates.
For aggregate reporting, the age groups requested were: 
< 15, 15–19, 20–24, 25–34, 35–44, 45–54, 55–64 and ≥65 
years. If data on age were unavailable or provided in an 
incompatible format, the specific country was excluded 
from age-specific analyses. 
Italy reported using two data sources. One of these sources 
has national coverage but includes only a limited number 
of variables and was used for the demographic variable 
3 Eurostat database available here: http://epp.eurostat.ec.europa.eu
2. Data collection and presentation
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analysis. This data source was used for the calculation 
of national rates and for breakdown of the data by age 
and gender. The other data source in Italy is a sentinel 
system covering an estimated 73% of the population and 
includes epidemiological data on a range of variables. 
The sampled population in this sentinel data source is 
considered representative of the wider population and 
this source was used for epidemiological variable analyses 
such as the reported route of transmission, testing loca-
tion, vaccination status, etc. 
2.5. Quality and completeness 
of reporting
Liechtenstein did not provide any data on hepatitis  B 
and C and is omitted from all the tables presenting the 
data per country. France was unable to provide any data 
on hepatitis C and is omitted from the tables presenting 
hepatitis C data.
Case classification (confirmed/other)
A few countries have submitted cases with ‘unknown’ or 
‘probable’ case classification. The revised EU case defini-
tions do not include the classification of cases as ‘probable’. 
In the enhanced data collection, only confirmed cases 
or cases classified as ‘unknown’ were accepted. Some 
countries uploaded data using previous case definitions 
which included probable cases. All cases were included 
in the analyses. 
Case-based and aggregate reports
For hepatitis  B and  C, it was agreed to collect the data 
for 2006 to 2011 in case-based format, where possible. 
Aggregate data was also accepted if case-based data were 
not available. Data completeness is affected by the use 
of aggregate data formats as only limited information is 
provided in the aggregate format (gender, age). The propor-
tion of cases in case-based format differs between the two 
diseases and over time (Table 1). In 2006, five countries 
uploaded data for hepatitis B using the aggregate format, 
but in 2011, all but one country uploaded case-based data. 
For hepatitis C, five countries used the aggregate format 
in 2006, but only two used this format in 2011. 
Completeness of data 
The completeness of reporting is an important attribute 
for the quality and interpretation of the data. For the 
period from 2006 to 2011, 92 365 cases of hepatitis B have 
been reported from 29 countries with varying degrees of 
completeness over time; and 175 189 cases of hepatitis C 
from 28 countries. 
In Annex 4, the completeness of data reporting is presented 
for the total database, for 2006–2011 and for 2006 and 2011 
separately. This table shows the completeness by variable 
with the number of countries reporting and the minimum 
and maximum values for country-specific completeness. 
For both diseases, there was an increase in the number 
of countries reporting across most variables from 2006 
to 2011. The overall completeness of reporting for both 
diseases was highest for the ‘age’ and ‘gender’ variables 
at over 96%. Overall, the completeness of the StageHEP 
variable, which defines the disease status, was 77.8% 
for hepatitis  B and 10.8% for hepatitis  C. Although the 
completeness of this variable improved, this was greater 
for hepatitis  B than for hepatitis  C. For hepatitis  C, the 
minimum reporting completeness for a country increased 
from 0.6% in 2006 to 4.4% in 2011. 
‘HIV status’, ‘complications’, ‘sex worker’ and ‘genotype’ 
had the lowest overall completeness across the period for 
both infections. The overall completeness for ‘sex worker’ 
across the whole period was 5.1% for hepatitis B and 1.3% 
for hepatitis C. In 2011, only two countries provided geno-
type information for hepatitis B, and only six countries did 
so for hepatitis C. 
Table 1: Number of cases reported for hepatitis B and C and the percentage of case-based data in 2006 and 2011, and 
from 2006–2011
2006–2011 2006 2011
Total number of cases Case-based (% total) Total number of cases Case-based (% total) Total number of cases Case-based (% total)
Hepatitis B 92 365 81.6 12 642 85.4 17 025 98.0
Hepatitis C 175 189 90.3 27 344 85.1 29 896 92.5
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Table 2: Hepatitis B: data source, type of surveillance data and the surveillance period 
Country Datasource Type * Enhanced data Period Case definition(s) used 
Austria AT-Epidemiegesetz C Yes (all years) 2006–2011 EU 2008
Belgium BE-FLA_FRA A No 2006–2009 National
Bulgaria
BG-NATIONAL_SURVEILLANCE A No 2007–2011 EU 2002
BG-MOH A No 2006 EU 2002
Cyprus CY-NOTIFIED_DISEASES C No 2007–2011 EU 2008
Czech Republic CZ-EPIDAT C Yes (2007-2011) 2007–2011 EU 2012
Denmark DK-MIS C Yes (all years) 2006–2011 National
Estonia
EE-HBV/GIARDIASIS** C Yes (all years) 2007–2011 EU 2012
EE-HEP_CHRONIC A No 2006–2009 EU 2012
Finland FI-NIDR C Yes (all years) 2006–2011 EU 2012
France FR-MANDATORY_INFECTIOUS_DISEASES C Yes (all years) 2006–2011 EU 2012
Germany DE-SURVNET@RKI-7.1/6 C Yes (all years) 2006–2011 National
Greece GR-NOTIFIABLE_DISEASES C Yes (all years) 2006–2011 EU 2008
Hungary HU-EFRIR C Yes (all years) 2006–2011 EU 2012
Iceland IS-SUBJECT_TO_REGISTRATION C Yes (2010 and 2011 only) 2007–2011 EU 2012
Ireland IE-CIDR C Yes (all years) 2006–2011 EU 2012
Italy
IT-SEIEVA*** C Yes (all years) 2006–2011 EU 2012
IT-NRS C No 2007–2011 National
Latvia LV-BSN C Yes (all years) 2006–2011 EU 2012
Lithuania
LT-COMMUNICABLE_DISEASES A No 2006-2009 EU 2012
LT-COMMUNICABLE_DISEASES C Yes 2010-2011 EU 2012
Luxembourg LU-SYSTEM1 C No 2007–2011 National
Malta MT-DISEASE_SURVEILLANCE C Yes 2007–2011 EU 2012
Netherlands NL-OSIRIS C Yes (all years) 2007–2011 EU 2012
Norway NO-MSIS_A C Yes (all years) 2006–2011 EU 2012
Poland
PL-NATIONAL_SURVEILLANCE C Yes 2010-2011 EU 2008
PL-NATIONAL_SURVEILLANCE A No 2006-2009 EU 2008
Portugal PT-HEPATITISB C Yes (2010 only) 2007–2011 National (2007–2009) EU 2012 (2010–2011)
Romania RO-RNSSy C Yes (all years) 2006–2011 EU 2012
Slovakia SK-EPIS C Yes (all years) 2006–2011 EU 2012
Slovenia SI-SURVIVAL C Yes (all years) 2006–2011 National (2006–2007) EU 2012 (2008–2011)
Spain ES-STATUTORY_DISEASES C No 2007–2011 EU 2008
Sweden SE-SMINET C Yes (all years) 2006–2011 EU 2012
United Kingdom UK-HEPATITISB C Yes (all years) 2006–2011 EU 2012
*Legend: type: aggregated (A); case-based (C).
**Acute data only 2007 -2009; acute and chronic data 2010-2011. 
**IT-SEIEVA data source used for epidemiological variables only.
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3.1. Key results
•	 In	2011,	17	025	cases	of	hepatitis B	were	reported	from	
28 EU/EEA Member States (no data from Belgium or 
Liechtenstein). 2 812 (16.5%) of these cases were reported 
as acute, 11 557 (67.9%) of cases were chronic and 2 312 
(13.6%) were classified as ‘unknown’. 
•	 The	rates	of	reported	chronic	infections	were	considerably	
higher than acute infections but with marked variations 
between countries.
•	 Hepatitis B	was	more	often	reported	in	men	than	women	
(overall male-to-female ratio of 1.5:1), with an overall rate 
of 4.1 cases per 100 000 for men and 2.7 for women. The 
most affected age group were those between 25 and 34 
years old, accounting for 32.9% of cases with rates of 
8.8 cases per 100 000 in males and 7.7 cases per 100 000 
in females. 16.7% of cases were aged under 25 years.
•	 In	 2011	 heterosexual	 transmission	 (23.4%),	 nosoco-
mial transmission (23.2%), injecting drug use (13.4%) 
and transmission among men who have sex with men 
(MSM) (10.3%) were most commonly reported for acute 
infections. Mother-to-child transmission was the most 
common route (67.3%) for chronic cases 
•	 Trends	over	time	are	difficult	to	interpret	in	the	light	of	
changes in case definitions and reporting practices in 
several countries during this period. However, across 
acute cases, there is a slight downward trend in rates over 
time which may reflect the widespread implementation 
of vaccination programmes. For chronic cases, there is 
an increase in the number and rates of cases over time 
which may reflect increased testing and changes in 
migration. 
3.2. Source of data
Between 2006 and 2011, hepatitis B data were available 
from all countries except Liechtenstein, although some 
countries were unable to report across the whole period. 
The data for 2011 represent confirmed cases from all coun-
tries. Data prior to 2011 includes probable cases from a 
number of countries which relates to the difficulties in 
providing data according to the new case definitions and 
in distinguishing between acute and chronic disease.
All countries had national coverage with the exception 
of the United Kingdom which was unable to submit data 
for Scotland. Table 2 specifies the source of the data, the 
type of data (aggregate or case-based), the availability of 
enhanced data, the case definitions used and the period of 
availability. This table shows the heterogeneity in surveil-
lance systems between countries and within countries 
over time. 
Most countries submitted case-based data. Of the five 
countries that submitted aggregate data over the course 
of the reporting period, three were able to submit case-
based data for 2011 (Belgium was unable to submit any 
data for 2011). Twenty seven countries were able to provide 
enhanced data, although several of these countries were 
only able to submit enhanced data for the latter part of 
the reporting period.
Comparison of hepatitis B data across Europe is difficult 
because of the heterogeneity in the case definitions used 
and in reporting systems. Although 18 countries were able 
to provide data in 2011 using the revised case definition 
(EU 2012), five of these countries submitted data on acute 
cases only (France, Hungary, Lithuania, Portugal and 
Romania). Data provided by the countries according to the 
previous EU case definitions (EU 20084 and EU 20025) only 
include acute cases of hepatitis B. In 2011 four countries 
(Denmark, Germany, Italy and Luxembourg) provided data 
according to their national case definitions, which include 
both acute and chronic cases for Denmark and only acute 
cases for the Germany, Italy and Luxembourg. It should 
also be taken into account that in some countries the case 
definitions changed between 2006 and 2011 with these 
countries using the revised case definition only for the 
latter part of the time period.
3.3. Demographic data 
In 2011, 17 025 cases of hepatitis  B were reported from 
28 countries (no data from Belgium and Liechtenstein), 
resulting in an overall crude rate of 3.5 per 100 000 popula-
tion. There was very little difference between the crude and 
age-standardised rates across countries and the overall 
age-standardised rate was the same as the crude rate.
Of all cases reported in 2011, 2 812 cases (16.5%) were 
reported as acute, 11 557 (67.9%) of cases were chronic and 
2 312 (13.6%) were classified as ‘unknown’. Three hundred 
and forty four cases (2.0%) could not be classified as acute, 
chronic or unknown. 
In 2011, 23 countries were able to provide data on acute 
infections. The number of cases ranged from one case in 
Portugal and two cases in Iceland to 688 cases in Germany. 
The rate of acute cases in 2011 showed less extreme varia-
tion ranging from <0.1 in Portugal to 2.4 cases per 100 000 
in Latvia. The overall notification rate for acute cases of 
hepatitis B was lower than the rate for chronic cases or 
cases classified as ‘unknown’. 
4 2008/426/EC: Commission Decision of 28 April 2008 amending 
Decision 2002/253/EC laying down case definitions for reporting 
communicable diseases to the Community network under Decision No 
2119/98/EC of the European Parliament and of the Council
5 2002/253/ED: Commission Decision of 19 March 2002 laying 
down case definitions for reporting communicable diseases to the 
Community network under Decision No 2119/98/EC of the European 
Parliament and of the Council
3. Hepatitis B
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Figure 1: Number of reported acute hepatitis B cases per 100 000 population in EU/EEA countries, 2011
Source, country reports: Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France*, Germany, Greece, Hungary, Iceland, Ireland, Latvia, 
Lithuania, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom (excluding Scotland).
*Under-reporting was estimated in France to be 85% for acute hepatitis B cases in 2010.
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Figure 2: Number of reported chronic hepatitis B cases per 100 000 population in EU/EEA countries, 2011 
Source, country reports: Austria, Denmark, Estonia, Finland, Ireland, Latvia, Malta, The Netherlands, Norway, Slovakia, Slovenia, Sweden, United Kingdom (excluding 
Scotland).
Liechtenstein
Luxembourg
Malta
Non-visible countries
Excluded
< 3.0
3.0–8.9
9–14.4
No data
17
Hepatitis B and C surveillance in Europe 2006–2011SURVEILLANCE REPORT
Figure 3: Number of acute and chronic hepatitis B cases per 100 000 population in nine EU/EEA countries, by year, 
2006–2011
Source: Data from countries with consistent reporting of both acute and chronic infections between 2006 and 2011 (Denmark, Estonia, Finland, Ireland, Norway, 
Slovakia, Slovenia, Sweden and the United Kingdom (excluding Scotland)).
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Figure 5: Number of chronic hepatitis B cases per 100 000 population in nine EU/EEA countries, 2006–2011
Source: Country reports from countries with consistent reporting of both acute and chronic infections between 2006 and 2011 (Denmark, Estonia, Finland, Ireland, 
Norway, Slovakia, Slovenia, Sweden and the United Kingdom (excluding Scotland)).
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Figure 4: Number of acute hepatitis B cases per 100 000 population in nine EU/EEA countries, 2006 2011
Source: Country reports from countries with consistent reporting of both acute and chronic infections between 2006 and 2011 (Denmark, Estonia, Finland, Ireland, 
Norway, Slovakia, Slovenia, Sweden and the United Kingdom (excluding Scotland)).
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Figure 6: Male-to-female ratio in acute hepatitis B casesa, by countryb, EU/EEA countries, 2011c
a Countries were included if they were able to present data by acute disease status or they used a case definition that included only acute cases (e.g. EU 2002/2008).
b Under-reporting was estimated in France to be 85% for acute hepatitis B cases in 2010.
c Data for United Kingdom excludes Scotland.
The number of males was greater than the number of females for acute, chronic and unknown cases for every year, but this difference was greater among acute cases 
than chronic cases. The number of cases per 100 000 population were also higher in males than females and these rates were highest among chronic cases (see 
table 3). Whilst the acute rates in both males and females showed a downward trend over time, rates among chronic cases by gender increased.
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Table 3: Number of reported hepatitis B cases per 100 000 population by stage of infection, gender and year in EU/EEA 
countries, 2006–2011
Year All cases Acute cases Chronic cases UnknownMale Female Male Female Male Female Male Female
2006 4.0 2.9 1.7 0.9 5.3 4.7 1.3 1.2
2007 4.1 2.5 1.5 0.8 7.0 5.7 2.2 1.6
2008 4.1 2.6 1.4 0.7 7.1 5.7 2.2 1.6
2009 4.2 2.7 1.2 0.6 9.1 6.7 2.6 1.7
2010 4.3 2.7 1.3 0.6 10.7 8.0 2.1 1.3
2011 4.1 2.7 1.3 0.6 13.7 10.6 1.9 1.1
Source, country reports: Austria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France*, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom (excluding Scotland).
* Under-reporting was estimated to be 85% for acute hepatitis B cases in France in 2010.
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Figure 1 shows the rates of acute hepatitis B across EU/ EEA 
countries in 2011. Countries were included if they were able 
to present data by acute disease status or if they used a 
case definition that included only acute cases (e.g. EU 
2002/2008). Countries were not included if they uploaded 
data using a national case definition and they were unable 
to define the cases as acute or chronic. 
Fourteen countries were able to provide data on chronic 
infections in 2011. The number and rates for chronic infec-
tions show considerably greater variation than acute cases. 
Rates of newly diagnosed chronic infections ranged from 
<0.1 case per 100 000 in Romania to 14.4 per 100 000 
population in Norway (figure 2 and annex 5), while numbers 
ranged from one case in Romania to 6 589 in the UK.
Trends are difficult to interpret due to the changes in 
reporting practice and case definitions. The comparison of 
data across countries over time is best undertaken through 
considering countries with stable reporting over the six year 
period. There were nine countries that provided continuous 
data on both acute and chronic cases, indicating that there 
is a decline in the overall number of acute infections over 
time and a steady rise in the number of newly identified 
chronic infections (figure 3). The chronic to acute rate ratio 
across these nine countries over this period increased from 
4.3 in 2006 to 11.2 in 2011.
Among the nine countries that provided consistent data on 
both acute and chronic infections, there were differences 
in the trends of acute rates (see figure 4). Most countries 
reported a small decline in rates of acute hepatitis B and 
this decline was most marked in Estonia and Norway. 
The United Kingdom showed no obvious trend across this 
period with rates fluctuating around 0.8 to 0.9 cases per 
100 000 population.
The rates of chronic cases of hepatitis B in these nine coun-
tries across the period shows a mixed picture as illustrated 
in figure 5. There is an increasing trend in some countries 
(Estonia, Norway, Slovakia, Slovenia, Sweden and UK) but 
a declining trend in others (Denmark, Finland and Ireland).
In 2011, 9 835 of all reported cases were in males (4.1 per 
100 000) and 6 902 cases in females (2.7 per 100 000). This 
represents an overall male-to-female ratio of 1.5:1. This ratio 
varied considerably between countries in 2011, ranging 
from 0.7 in Denmark to 4.4 in Luxembourg. Some of this 
variation may be related to the differences in case reporting 
with the overall male-to-female ratios highest amongst 
countries that only reported acute cases (Luxembourg, 
Cyprus, Hungary and Greece). The male-to-female ratio 
was higher among acute cases than chronic cases in most 
countries and for acute cases ranged from <0.1 in Portugal 
to 5.2 in Ireland (see figure 6).
The number of males was greater than the number of 
females for acute, chronic and unknown cases for every 
year, but this difference was greater among acute cases 
than chronic cases. The number of cases per 100 000 
population were also higher in males than females and 
these rates were highest among chronic cases (see table 3). 
Whilst the acute rates in both males and females showed 
a downward trend over time, rates among chronic cases 
by gender increased.
In 2011, around a third of all hepatitis B cases reported were 
in the 25 to 34 age group (32.9% of the total). The highest 
rates in both males and females were in this age group at 
8.8 per 100 000 in males and 7.7 per 100 000 in females 
(see figure 7). Across all age groups, except the 20 to 24 
age group, rates were higher among males than females 
and 16.7% of all cases reported in 2011 were aged under 
25 years. There has been a decline in this proportion since 
2006 when a total of 22.3% of cases were aged under 25.
In 2011, for both acute and chronic cases the rates were 
highest in the 25 to 34 age group at 1.6 and 26.1 cases per 
100 000 respectively. The age distribution among reported 
cases of acute and chronic infections was similar, with 
17.1% of acute cases and 17.6% of chronic aged under 25 
years (see figure 8).
3.4. Enhanced surveillance data
Although the number of countries reporting information 
on transmission category increased between 2006 and 
2011, information on transmission was only available for 
17.8% of cases in 2011 (see Annex 4). There are differences 
between countries in the reported routes of transmission, 
however it is difficult to identify any trends as reporting 
across most countries was patchy and incomplete. 
During 2011, for acute cases, heterosexual transmission 
was reported as the most common route of transmission 
(23.4%), followed by nosocomial transmission (23.2%), 
injecting drug use (13.4%) and MSM (10.3%). Between 2010 
and 2011 there was an increase in the proportion of acute 
cases with nosocomial and non-specified sexual trans-
mission. These differences may be related to changes in 
completeness of reporting over time. Indeed, the increase in 
reported nosocomial transmission between 2010 and 2011 
can all be attributed to the improved reporting by Romania. 
In 2011, mother-to-child transmission was the most common 
route (67.3%) for chronic cases, followed by ‘other’ routes 
(9.3%) and heterosexual transmission (6.1%). There was 
very little change in the reported transmission categories 
between 2010 and 2011.
There are some differences in reported transmission cate-
gory by gender across all cases (see figure 9). Mother-to-
child transmission was more commonly reported in females 
(50.6%) than among males (36.2%). Injecting drug use was 
more common in males (8.9%) than females (4.6%) and 
un-specified sexual transmission was also more common 
among males (7.3%) than females (4.9%).
There was also minor variation in the reported transmis-
sion category by age. In acute cases aged 30 or under, 
injecting drug use was more commonly reported (24.9%) 
than among cases aged over 30 years (7.7%). Heterosexual 
transmission was also more commonly reported among 
acute cases aged 30 or under (26.2%) than among cases 
aged over 30 (22.0%). For chronic cases, mother-to-child 
transmission dominated across the age groups but was 
20
SURVEILLANCE REPORTHepatitis B and C surveillance in Europe 2006–2011
Figure 7: Number of reported hepatitis B cases (acute, chronic and unknown) per 100 000 population by age group and 
gender, in EU/EEA countries, 2011
Source, country reports: Austria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, Latvia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom (excluding Scotland).
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Figure 8: Number of reported hepatitis B cases per 100 000 by age and disease status, in EU and EEA countries, 2011
Source: Country reports: Austria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Latvia, Netherlands, Norway, Romania, 
Slovakia, Slovenia, Sweden, United Kingdom (excluding Scotland).
0
5
10
15
20
25
30
≥ 6555–6445–5435–4425–3420–2415–195–14< 5 
Chronic
Acute
Ra
te
 p
er
 10
0 
00
0
Age group
Unknown
Table 4: Transmission category of hepatitis B cases by disease status, in EU/EEA countries, 2011* 
Transmission category Acute (%) Chronic (%) Unknown (%) Total (%)
Heterosexual transmission 23.4 6.1 18.4 12.6
Nosocomial (includes hospital, nursing home, etc.) 23.2 2.9 2 10.3
Injecting drug use 13.4 3.5 8.2 7.2
Men who have sex with men 10.3 2.4 12.2 5.4
Sexual transmission (not specified) 9.3 3.9 34.7 6.4
Non-occupational injuries (needle stick, bites, tattoos, piercings) 6.6 1.1 0 3.1
Household 6.3 0.8 2 2.8
Other 5.3 9.3 4.1 7.8
Haemodialysis 0.8 0 0 0.3
Blood and blood products 0.6 2.4 2 1.8
Mother-to-child transmission 0.4 67.3 10.2 41.8
Needle-stick and other occupational exposure 0.4 0.3 6.1 0.4
Organ and tissues 0 0 0 0
Total 100.0 100.0 100.0 100.0
Source, country reports: Czech Republic, Denmark, Estonia, Finland, France**, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, 
Poland, Romania, Slovakia and Sweden. 
*Analyses undertaken by disease status category for all cases where transmission category is not classified as ‘unknown’
**Under-reporting was estimated to be 85% for acute hepatitis B cases in France in 2010.
There are some differences in reported transmission category by gender across all cases (see figure 9). Mother-to-child transmission was more commonly reported in 
females (50.6%) than among males (36.2%). Injecting drug use was more common in males (8.9%) than females (4.6%) and un-specified sexual transmission was also 
more common among males (7.3%) than females (4.9%). 
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slightly more common among those aged 30 or under 
(69.3%) than among those aged over 30 (66.0%).
Information on the type of clinical service or testing facility 
where patients were tested for hepatitis was poorly reported 
with information available for only 1 998 cases (11.7%) 
from nine countries. Of these cases, the most common 
reported place of testing was the infectious disease clinic 
(36.3%) followed by the family practice (general practice) 
clinic (23.9%). There was some variation in the reported 
testing facility by disease status with a greater proportion 
of chronic cases reported to be tested at antenatal clinics 
(14.3%) and via general practice (29.5%) than acute cases 
(0.6% and 7.1% respectively). 
Information on healthcare worker status was completed for 
only 3 575 cases (21.0%) of cases in 2011 from 18 countries. 
Of these cases, 43 (1.2%) were reported to be healthcare 
workers (7 acute, 35 chronic and 1 unknown). 
Information on hepatitis B vaccination status was provided 
by 18 countries for 4 025 cases (23.6%). Of these cases, the 
majority (95.6%) were reported as not being vaccinated 
with only 39 (1.0%) being reported as fully vaccinated and 
38 (0.9%) as partly vaccinated. 
In 2011, 18 countries provided information on 6 662 cases 
(39.1%) for the variable ‘imported’ (Annex 5). Of these 
cases 3 507 (52.6%) were reported as being imported. 
There was considerable variation in the proportion of 
imported cases for acute and chronic infections. Of acute 
cases, 6.5% of cases with available information were 
classified as imported compared with 87.0% for chronic 
cases. Among acute cases the proportion of ‘imported’ 
cases ranged from 0% (Austria, Czech Republic, Germany, 
Greece, Hungary and Poland) to 69.2% in Finland. Among 
chronic cases this proportion ranged from 0% in Estonia to 
96.1% in Sweden. Some of this variation between countries 
is likely be related to differences in data completeness and 
fluctuations caused by low numbers in some countries. 
There was some variation in the reported transmission 
route according to whether the case was imported. In 
particular, of cases classified as ‘imported’ with complete 
information on transmission (1 600), 1 163 cases (72.7%) 
were recorded as mother-to-child transmission. Of these 
1 163 cases, 99.6% were reported as chronic. Among cases 
classified as not being ‘imported’ 185 cases were reported 
to have been infected through heterosexual transmission 
(77.8% acute), 136 through injecting drug use (66.2% acute) 
and 116 through nosocomial transmission (83.6% acute).
Data on the probable country of infection was provided by 
15 countries for a total of 3 443 cases. For these cases, a 
total of 137 different countries were reported. For 3 340 
cases (97.0%), the probable country of infection reported 
was different from the country reporting the case. 
Country of birth and country of nationality were compared 
to the ‘reporting country’ as a crude analysis of whether 
cases may have been infected outside the reporting country, 
however both country of birth and country of nationality 
were poorly completed variables across many countries 
and the data incomplete. In 2011, the proportion of cases 
where the reporting country was different from the country 
of birth or nationality (3 882 cases (22.9%)) was greater 
than the proportion of cases where the reporting country 
was the same (1 256 cases (7.4%) in 2011) (see annex 5). 
In 35.4% of acute cases the reporting country was different 
to the country of birth or nationality and for 26.9% cases 
it was the same. The difference was more marked for 
chronic cases, with the data among cases with complete 
information indicating that for 22.0% cases the reporting 
country was different from the reported country of birth or 
country of nationality, and for 3.1% cases it was the same.
Data on the outcome of hepatitis B infection was reported 
for 5 172 cases (30.4%) from 22 countries in 2011. Of these 
cases, 58 were reported to have died.
Figure 9: Transmission category of all hepatitis B cases (acute, chronic and unknown) by gender, in EU/EEA countries, 2011 
Source, country reports: Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, 
Poland, Portugal, Slovakia, Sweden, United Kingdom (excluding Scotland).
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3.5. Discussion
The data collected from countries highlights a significant 
burden of infection resulting from hepatitis B in countries 
across Europe with variation between countries in reported 
cases of both acute and chronic infections. In countries 
that reported both acute and chronic cases, there were 
markedly more chronic cases reported than acute cases. 
There is a downward trend in the notification rate for 
acute cases which is likely to be related to the on-going 
implementation of vaccination programmes across Europe 
[2, 3]. For chronic cases, there is a rise in the number and 
rate over time. This increase is most likely to be related 
to high levels of testing in several countries as a result of 
screening and testing programmes among key populations. 
There are major differences in both the numbers and rates 
of acute and chronic cases between countries which are 
not just related to differences in the case definitions used. 
Six countries had rates of acute hepatitis below 0.5 per 
100 000 in 2011 (Denmark, Finland, France, Greece, Poland 
and Portugal). Whilst these figures may reflect various 
local factors, such as a decline in local transmission due 
to effective prevention and control programmes, it is likely 
that under-reporting is also a key issue, with France esti-
mating this to be as high as 85% in 2010 (Larsen C. INVS 
France, email communication, 26.03.2013).
The variation in the numbers of chronic cases between 
countries is more marked than acute cases but the rates 
show less variation. Ireland, Norway, Sweden and the 
United Kingdom (excluding Scotland) all reported rates of 
chronic hepatitis  B over 10.0 cases per 100 000 in 2011. 
The variation in the number of chronic cases is also very 
likely to be a reflection of the differences in testing and 
screening practices between countries. A contributory 
factor behind the high rates in these countries is likely to 
be the inward migration of chronic cases from countries 
with a high prevalence of hepatitis  B. Indeed, the data 
on imported status for chronic cases in Sweden and the 
Netherlands was fairly complete and suggests that a high 
proportion of these cases are imported.
Hepatitis B varies by age and gender and is most common 
among young male adults. There were also gender differ-
ences between acute and chronic cases with relatively 
more male cases among acute cases than chronic cases. 
This variation may be partly explained by the widespread 
screening of pregnant women that occurs in many countries 
which identifies many cases of chronic infection among 
women. In addition, sexual modes of transmission and 
injecting drug use were more common among males and 
for acute cases. 
Heterosexual transmission, nosocomial transmission, 
injecting drug use and transmission among MSM were most 
commonly reported for acute cases and mother-to-child 
transmission was the most common route for chronic cases. 
The reported routes of transmission for acute cases reflect 
the current transmission of hepatitis B in countries. The 
routes of transmission for chronic cases reflects transmis-
sion that may have occurred many years previously and the 
data indicates that for the majority of cases infection was 
acquired through mother-to-child transmission. Although 
issues with data completeness limit the conclusions that 
may be drawn, the available data suggests that many 
of these mother-to-child transmissions may have been 
acquired in a different country to the reporting country. 
The completeness of data was heterogeneous across 
countries and is a serious limitation. It seems that over 
time more countries were able to provide data and that the 
completion has improved. There was also some variation 
in the case definitions used across countries and some 
changes in case definitions over time within countries 
with increasing number of countries able to use the new 
EU case definitions. However, some of the countries able 
to use the new case definitions could still only report acute 
cases as only acute hepatitis is notifiable by national law. 
These differences provide challenges to the interpretation 
of the data, especially when considering the trends in 
the number of cases over time, the differences between 
countries and the conclusions that can be drawn for many 
of the epidemiological variables. Indeed, the analyses for 
several of the enhanced epidemiological variables were 
hampered by poor reporting. It is hoped that over time 
the completeness of reporting will improve to facilitate a 
fuller analysis of all the data. 
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4. Hepatitis C
24
SURVEILLANCE REPORTHepatitis B and C surveillance in Europe 2006–2011
Table 5: Hepatitis B: data source, type of surveillance data and the surveillance period 
Country Datasource Type * Enhanced data Period Case definition(s) used Case definition(s) used 
Austria AT-Epidemiegesetz C Yes (all years) 2006–2011 EU 2008 Acute and chronic – differentiated
Belgium BE-FLA_FRA A No 2006–2009 National No data
Bulgaria BG-national_surveillance A No 2007–2011 EU 2008 Acute and chronic – Undifferentiated
BG-MOH A No 2006 EU 2008 -
Cyprus CY-NOTIFIED_DISEASES C No 2007–2011 EU 2008 Acute and chronic – Undifferentiated
Czech Republic CZ-EPIDAT C Yes (2007–2011) 2007–2011 EU 2008 Acute and chronic – Undifferentiated
Denmark DK-MIS C Yes (all years) 2006–2011 National Acute and chronic – differentiated
Estonia EE-HCV/CHLAMYDIA** C Yes (2007–2011) 2007–2011 EU 2012 Acute and chronic – differentiated
EE-HEP_CHRONIC A No 2006–2009 EU 2012 -
Finland FI-NIDR C Yes (all years) 2006–2011 EU 2012 Acute and chronic – Undifferentiated
France - - No - - No data
Germany DE-SURVNET@RKI-7.1/6 C Yes (all years) 2006–2011 EU 2012 Acute and chronic – Undifferentiated
Greece GR-NOTIFIABLE_DISEASES C Yes (all years) 2006–2011 EU 2008 Acute and chronic – differentiated
Hungary HU-EFRIR C Yes (all years) 2006–2011 EU 2012 Acute only
Iceland IS-subject_to_registration C Yes (2010– 2011) 2007–2011 EU 2012 Acute and chronic – Undifferentiated
Ireland IE-CIDR C Yes (all years) 2006–2011 EU 2012 Acute and chronic – differentiated
Italy IT-SEIEVA*** C Yes (all years) 2006–2011 EU 2012 -
IT-NRS C No 2007–2011 National Acute and chronic – Undifferentiated
Latvia LV-BSN C Yes (all years) 2006–2011 EU 2012 Acute and chronic – Undifferentiated
Lithuania LT-communicable_diseases A No 2006-2009 EU 2012 -
LT-communicable_diseases C Yes (2010–2011) 2010-2011 EU 2012 Acute only
Luxembourg LU-SYSTEM1 C No 2007–2011 National Acute and chronic – Undifferentiated
Malta MT-DISEASE_SURVEILLANCE C Yes (2009–2011) 2007–2011 EU 2008 (2007 – 2008)  EU 2012 (2009 – 2011) Acute only
Netherlands NL-OSIRIS C Yes (2010–2011 only) 2007–2011 EU 2008 Acute only
Norway NO-MSIS_A C Yes (all years) 2006–2011 EU 2012 Acute and chronic – Undifferentiated
Poland PL-NATIONAL_SURVEILLANCE A No 2006-2011 EU 2008 Acute and chronic – Undifferentiated
Portugal PT-HEPATITISC C Yes (2010–2011) 2007–2011  National Acute only
Romania RO-RNSSy C Yes (all years) 2006–2011 EU 2012 Acute and chronic – Undifferentiated
Slovakia SK-EPIS C Yes (all years) 2006–2011 EU 2012 Acute and chronic – differentiated
Slovenia SI-SURVIVAL C Yes (all years) 2006–2011 National (2006-2007) EU 2012 (2008-2010)
Acute and chronic 
– differentiated
Spain ES-STATUTORY_DISEASES C No 2007–2008 EU 2008 No data
Sweden SE-SMINET C Yes (all years) 2006–2011 EU 2012 Acute and chronic – undifferentiated
United Kingdom UK-HEPATITISC C Yes (all years) 2006–2011 EU 2012 Acute and chronic – differentiated
*Legend: type: aggregated (A); case-based (C).
**Acute data only 2007 -2009; acute and chronic data 2010-2011. 
**IT-SEIEVA data source used for epidemiological variables only.
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4.1. Key results
•	 In	2011,	29	896	cases	of	hepatitis C	were	reported	from	
26 EU/EEA Member States, representing an overall noti-
fication rate of 7.8 cases per 100 000 population. 
•	 Only	12	countries	in	2011	were	able	to	classify	cases	as	
acute or chronic, with complete data available for only 
13.3% of cases overall. Of cases reported in 2011, 398 
cases (1.3%) were reported as ‘acute’, 2 913 (9.7%) of 
cases were ‘chronic’ and 24 337 (81.4%) were ‘unknown’. 
•	 The	 overall	male-to-female	 ratio	was	 2:1.	 The	most	
affected age group are those between 25 and 34 years 
old accounting for 28.2% of all cases. Eleven per cent 
of all cases were aged under 25 years. The notification 
rate was highest in the 25 to 34 age group at 23.5 per 
100 000 in males and 11.9 per 100 000 in females.
•	 The	most	common	route	of	transmission	reported	across	
all disease categories was injecting drug use, accounting 
in 2011 for 78.1% of all cases with complete information. 
•	 Trends	over	time	are	difficult	to	interpret	due	to	changes	
in reporting practices in the use of case definitions and 
reporting practice over the period. 
4.2. Source of data
For 2006–2011, hepatitis  C data were available from all 
countries except Liechtenstein and France. Not all 28 
countries were able to provide data for every year. Overall, 
the reporting improved over the period with 26 countries 
reporting data in 2011 compared to 19 in 2006. Most cases 
reported from countries in 2011 were classified as confirmed 
except for 17 cases of ‘unknown’ classification from three 
countries (Latvia, Portugal and Slovakia). Data prior to 
2011 included cases classified as ‘probable’ which relates 
to the difficulties in providing data according to the new 
case definitions.
Of the 28 countries reporting data, all had national 
coverage. Table 5 specifies the source of the data, the 
type of data (aggregate or case-based), the availability of 
enhanced data, the case definitions used and the period 
of availability. This table highlights the significant hetero-
geneity in surveillance systems between countries and 
within countries over time. 
In 2011, 24 countries submitted case-based data. Five 
countries submitted aggregate data at some point over 
the five year reporting period, but three of these countries 
were able to submit case-based data for 2011. Twenty four 
countries were able to provide enhanced data, although for 
eight of these countries enhanced data were only available 
for the latter part of the reporting period.
Although 15 countries were able to provide data in 2011 
using the revised case definition (EU 2012), one of these 
countries (Lithuania) was only able to use the new case 
definition for data at the end of the reporting period. Three 
of these 15 countries just submitted data on acute cases 
as only acute hepatitis C is notifiable on a national basis 
(Hungary, Malta, Lithuania). Seven countries provided data 
according to the previous EU case definition (EU 2008) for 
hepatitis C which as discussed previously is similar to the 
revised EU case definition as it also captures data on both 
acute and chronic infections. Both case definitions include 
confirmed cases of hepatitis C of both acute and chronic 
status. The similarity between these two definitions means 
that hepatitis C data uploaded using either of these two 
case definitions is fairly comparable. 
Malta and Slovenia changed their case definitions between 
2007 and 2011.
4.3. Demographic data
In 2011, 29 896 cases of hepatitis  C were reported from 
26 countries (no data from Belgium, France, Liechtenstein 
and Spain). The overall notification rate was 7.8 cases per 
100 000 population. In 2011, the number of cases reported 
by countries ranged from 18 cases in both Malta (4.3 cases 
per 100 000) and Greece (0.2 cases per 100 000) to 12 196 
(19.5 cases per 100 000) in the United Kingdom. 
In 2011, 398 cases (1.3%) were reported as ‘acute’, 2 913 
(9.7%) as ‘chronic’ and 24 337 (81.4%) as ‘unknown’;2 248 
cases (7.5%) could not be classified at all according to 
disease status due to the format of the data provided. Only 
11 countries provided data on acute cases of hepatitis C in 
2011. The number of acute cases in 2011 ranged from two 
cases in Portugal (<0.1 cases per 100 000) to 171 cases in 
Austria (2.0 cases per 100 000). There were eight countries 
reporting chronic cases in 2011. The numbers of chronic 
cases showed great variation across countries from six 
cases in Greece (0.1 cases per 100 000) to 1 496 cases in 
the UK (2.4 cases per 100 000). The highest rate of chronic 
disease was observed in Estonia which reported 188 cases 
and had a notification rate of 14.0 cases per 100 000. The 
number of cases classified as ‘unknown’ ranged from one 
case in Greece (<0.1 cases per 100 000) to 10 070 in the 
United Kingdom (20.2 cases per 100 000).
The incompleteness of the data as defined by disease status 
limits the presentation of the data and the identification 
of geographical trends among acute and chronic cases. 
Figure 10 shows the overall notification rates of hepatitis C 
cases across EU/EEA countries. Countries were included if 
their surveillance system were known to capture data on 
both acute and chronic cases even if a sizeable proportion 
of the data was classified as ‘unknown’. As acute hepatitis C 
is usually asymptomatic or mild and difficult to diagnose 
clinically or serologically, most reported cases of hepatitis C 
in those countries where all types of viral hepatitis cases 
are notifiable are therefore likely to be chronic. Although 
4. Hepatitis C
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there are obvious limitations to this approach, it provides 
more complete data for comparison across countries. The 
map shows high overall rates of hepatitis C notifications 
in the north European countries and a suggestion of lower 
rates in Southern and East European countries. 
There are five countries that provided consistent data 
on acute cases over the six year reporting period (see 
figure 11). Estonia shows a marked declining trend over 
this period from 4.2 cases per 100 000 in 2006 to 1.2 cases 
per 100 000 in 2011. The remaining four countries show 
low level stable trends over the period.
Five countries reported chronic cases consistently across 
the six year period (figure 12). These five countries show 
relatively stable trends apart from Estonia which had 
increasing rates of chronic notifications from 10.7 cases 
per 100 000 population in 2006 to 14.0 in 2011.
Many countries were unable to use the StageHEP criteria to 
classify cases as either acute or chronic and consequently 
classified cases as ‘unknown’. As discussed previously, 
most of these ‘unknown’ cases are likely to be chronic due 
to the difficulties in identifying acute cases. Five countries 
reported ‘unknown’ cases consistently across the six year 
period (figure 13). Norway and Latvia show marked variation 
in rates of ‘unknown’ cases over the period which may be 
due to changes in reporting practice or diagnostic testing. 
The other countries show no obvious trends and the overall 
figures for these five countries are fairly stable over time.
In 2011, 18 159 of all reported cases for whom gender was 
reported were male (10.7 cases per 100 000) and 9 521 cases 
were females (5.4 cases per 100 000). This represents a 
male-to-female rate ratio of 2:1.This ratio varied little over 
time, but varied considerably between countries in 2011 
ranging from 1.1 in Romania to 55.9 in the Cyprus (see 
figure 14). The actual numbers of cases in Cyprus with 
information on gender were low which may explain some 
of this extreme variation.
The number of males was mostly greater than the number 
of females for acute, chronic and unknown cases for all 
countries across all years. Notification rates were higher 
in males than females across all disease types and were 
highest among cases classified as ‘unknown’ and lowest 
among cases classified as acute (see annex 5, table A15). 
In 2011, just over a half of all the hepatitis C cases reported 
were aged between 25 and 44 (53.5% of cases) and 11.0% 
of cases were aged under 25 years. The notification rate 
was highest for both males and females in the 25 to 34 age 
group at 23.5 per 100 000 in males and 11.9 per 100 000 
in females. For every age group except those aged 0 to 5 
Figure 10: Number of reported hepatitis C cases per 100 000 population in 21 EU/EEA countries, 2011
Source, country reports: Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Iceland, Ireland, Italy, Latvia, Luxembourg, Norway, 
Poland, Romania, Slovakia, Slovenia, Sweden, United Kingdom 
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Figure 11: Number of acute hepatitis C cases per 100 000 population in five EU/EEA countries, by year, 2006–2011
Source: Country reports from countries with consistent reporting of acute hepatitis C infections between 2006 and 2011 (Denmark, Estonia, Hungary, Slovakia, 
Slovenia).
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Figure 13: Number of ‘unknown’ hepatitis C cases per 100 000 population in five EU/EEA countries, by year, 2006–2011
Source: Country reports from countries with consistent reporting of ‘unknown’ hepatitis C infections between 2006 and 2011 (Finland, Germany, Latvia, Norway, 
Sweden).
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Figure 12: Number of chronic hepatitis C cases per 100 000 population in five EU/EEA countries, by year, 2006–2011
Source: Country reports from countries with consistent reporting of chronic hepatitis C infections between 2006 and 2011 (Denmark, Estonia, Slovakia, Slovenia, 
United Kingdom).
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Figure 14: Male-to-female ratio in hepatitis C cases in EU/EEA countries, 2011 
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Figure 15: Number of reported hepatitis C cases (acute, chronic and unknown) per 100 000 by age group and gender, in 
EU and EEA countries, 2011
Source, country reports: Austria, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, Malta, the Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Sweden, United Kingdom.
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and 5 to 14 the notification rates were considerably higher 
among males than females. 
The age distribution by disease status shows that reported 
cases of acute infection have a slightly younger profile 
than reported cases of chronic infection, with 27.4% of 
acute cases aged under 25 years compared to 8.2% of 
chronic cases
4.4. Enhanced surveillance data
The overall completeness of data provided regarding trans-
mission of hepatitis C was low with information complete 
for only 28.9% cases in 2011 (see annex 4). There are 
differences between countries in the reported route of 
transmission (see annex 5, table A6), but it is difficult to 
identify any trends as reporting across most countries 
was incomplete. 
Overall, the most commonly reported route of transmis-
sion was injecting drug use accounting for 78.1% of all 
cases in 2011 where transmission route was known (see 
table 6). The next most commonly reported transmission 
route was blood and blood products which accounted for 
8.1% of cases. Of cases reported as being transmitted 
through blood and blood products 99.8% of the cases 
were classified as chronic or ‘unknown’.
Across all disease status groups, injecting drug use was 
the most common route of transmission, although this 
proportion was lower among acute cases than among 
those classified as chronic or ‘unknown’. In acute cases, 
the other main routes of transmission included nosocomial 
transmission (16.9%) and transmission among men who 
have sex with men (24.4%). However, the number of acute 
cases with complete information on transmission was low 
so these figures may be subject to both fluctuation and 
reporting bias.
Between 2006 and 2011, there were a few changes in the 
reported transmission category. Table A8 in annex 5 shows 
the data by disease status and transmission category over 
the six-year period. Overall there was an increase in cases 
reported as male-to-male transmission or ‘not specified’ 
sexual transmission. For acute cases, there is a fall in the 
proportion of cases assigned as injecting drug use from 
40.6% in 2006 to 33.3% in 2011. There is a concurrent rise 
in the proportion of cases among MSM from 0.7% in 2006 
to 24.4% in 2011. 
The type of clinical service or testing facility where patients 
were tested for hepatitis was poorly reported with informa-
tion available for 4 811 cases from nine countries (Estonia, 
Hungary, Ireland, Latvia, Luxembourg, Malta, Portugal, 
Sweden, United Kingdom). Of these cases, the most common 
reported place of testing infectious was disease clinics 
(32.7%) followed by ‘other’ (23.6%), and general practice 
clinics (20.7%). 
Seventeen countries reported data for the ‘imported’ vari-
able for 12 111 cases. Of the 1 006 cases in 2011 reported by 
countries as being imported, 15 (1.5%) were in acute cases, 
294 (29.2%) were chronic cases and 697 (69.3%) were in 
cases whose disease status was unknown. 
Data on the outcome of hepatitis C infection was reported 
for 10 488 cases from 24 countries in 2011 (see table A14). 
Of these cases, 76 were reported to have died.
4.5. Discussion
The data presented indicates a high burden of hepatitis C 
infection in countries across Europe with considerable vari-
ation between countries in the number of reported cases.
Although some countries only reported acute cases, the 
vast majority of reported cases are classified as either 
‘chronic’ or ‘unknown’. As acute hepatitis C is difficult to 
diagnose clinically and serologically, it is likely that most 
of these ‘unknown’ cases are chronic cases. In countries 
able to define cases using the StageHEP criteria as acute or 
chronic there are markedly more chronic cases than acute 
cases reported. There was variation between countries in 
the reported cases of acute, chronic and ‘unknown’ cases. 
Table 6: Transmission category of hepatitis C cases by disease status in EU/EEA countries, 2011*
Transmission category Acute (%) Chronic (%) Unknown (%) Total (%)
Injecting drug use 33.3 83.7 78.4 78.1
Men who have sex with men 24.4 0.0 1.3 1.7
Nosocomial (includes hospital, nursing home, etc.) 16.9 4.7 1.7 2.5
Heterosexual transmission 7.5 2.5 1.4 1.7
Household 6.0 0.2 0.1 0.3
Non-occupational injuries (needle stick, bites, tattoos, piercings) 6.0 1.9 1.2 1.4
Sexual transmission (not specified) 2.5 0.5 4.3 3.6
Other 2.0 3.0 0.9 1.3
Haemodialysis 1 0.0 0.4 0.4
Blood and blood products 0.5 2.7 9.4 8.1
Mother-to-child transmission 0.0 0.3 0.6 0.5
Needle-stick and other occupational exposure 0.0 0.4 0.3 0.3
Organ and tissues 0.0 0.0 0.0 0.0
Total 100.0 100.0 100.0 100.0
Source, country reports: Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, 
Portugal, Slovakia, Sweden and United Kingdom.
*Analyses undertaken by disease status category for all cases where transmission category is not classified as ‘unknown’.
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This variation is likely to be related to a number of factors 
including the ability to define data by acute or chronic status 
as well as the considerable differences in the amount of 
diagnostic testing taking place between countries.
The data presented indicates hepatitis C to be an infec-
tion predominantly affecting young adult males, which 
reflects the demographic profile of the key risk groups. 
Male cases dominate acute and chronic infections and 
across all countries but there were considerable differences 
in the male-to-female ratio between countries. The source 
of this variation is not clear but it is probable that some 
of this variation may be explained by the small numbers 
resulting in fluctuations in the data. 
There are differences in age distribution between acute and 
chronic cases. These differences are likely to be related to 
the differences in ages of the different risk groups. Indeed, 
individuals infected with hepatitis C through MSM trans-
mission, which is more commonly reported among acute 
cases, tend to be younger than those infected through 
injecting drug use. 
Injecting drug use was the main route of transmission for 
all disease categories and across all countries, but was 
less frequently reported among acute cases. Analyses of 
the data showed an increasing proportion of cases among 
MSM over time. Several European countries have reported 
a rise in hepatitis C infections among HIV infected MSM 
[4] and routine screening of HIV positive MSM is under-
taken in these countries. It is possible that this screening 
has elevated the number of cases with the transmission 
category MSM among acute cases. 
The StageHEP variable, (which distinguishes stage of 
infection as acute, chronic and unknown), was consider-
ably less complete for hepatitis C than hepatitis B which 
reflects the complicated serology of hepatitis C and the 
difficulties in differentiating between acute and chronic 
infections. Over the whole period, this variable, which 
enables the breakdown of data by disease status, was only 
provided for 10.8% of cases. Although data completeness 
improved over time, many countries were only able to clas-
sify cases as ‘unknown’ and this is a significant limitation 
of the data collected. 
There was also some variation in the case definitions used 
across countries and over time. Both the EU 2008 and the 
EU 2012 definitions include acute and chronic cases, so 
reviewing data between countries using these two defini-
tions is less problematic than for hepatitis B. However, some 
of the countries using these definitions only provided data 
on acute cases, as only acute hepatitis C is notifiable on a 
national level, which is problematic due to the difficulties 
in easily identifying acute infections. These differences in 
the reporting of cases between countries and over time 
hamper a clear interpretation of the data. 
A further limitation of the data is the heterogeneity of the 
data completeness across both countries and variables. 
However, over the data collection period, more countries 
were able to provide data for each of the variables and 
data completion improved. Nevertheless, these differences 
provide challenges to the interpretation of the data, espe-
cially when considering the trends in the number of cases 
over the reporting period, the differences between coun-
tries and the conclusions that can be drawn for many of 
the epidemiological variables. 
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Table 7: Summary of key statistics of hepatitis B and C data in EU/EEA countries, 2011
Indicators 2011 Hepatitis B Hepatitis C
Number of countries reporting data in 2011:
Overall 28 26
Using EU 2012 case definition 18 15
Completeness of stageHEP variable, 2011 88.4% 13.3%
Rates per 100 000 population:
Acute 0.7 0.5
Chronic 8.0 2.9
Unknown 0.8 8.1
Total 3.5 7.8
Male-to-female rate ratio 1.5:1 2:1
% cases among 25 to 34 year olds 32.9% 28.2%
% cases aged under 25 16.7% 11.0%
Most common transmission category:
Acute Heterosexual transmission 23.4% Injecting drug use 33.3%
Chronic Mother-to-child 67.3% Injecting drug use 83.7%
All cases Mother-to-child 41.8% Injecting drug use 78.1%
Source, country reports: Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, 
Portugal, Slovakia, Sweden and United Kingdom.
*Analyses undertaken by disease status category for all cases where transmission category is not classified as ‘unknown’.
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This report presents the results from the first EU-wide 
data collection of enhanced hepatitis B and C surveillance 
data from EU/EEA Member States. The results indicate that 
surveillance systems for these infections across coun-
tries are both diverse and complex. The heterogeneity in 
reporting makes the interpretation of the distribution and 
trends of hepatitis B and C very challenging. It is therefore 
essential to have a clear understanding of the national 
surveillance systems. Although data for both infections 
improved in terms of completeness over 2006–2011 for 
many variables, this was a major challenge hampering 
the interpretation of results. 
The revised EU case definition developed for hepatitis B 
captures cases in both acute and chronic stages of the 
infection (or where the stage is unknown) to provide a more 
accurate assessment of the epidemiological situation. This 
distinction between acute and chronic cases of hepatitis B is 
important from a public health perspective to help evaluate 
the impact of control measures on transmission patterns 
and to guide future prevention strategies. The previous 
EU case definition for hepatitis C included the capture of 
both acute and chronic cases and was only revised very 
slightly to include the reporting of cases using the new 
antigen test and to exclude resolved cases. 
The overall comparison between hepatitis B and C with 
respect to numbers, rates, number of countries reporting, 
male-to-female ratio, age distribution and reported trans-
mission route are shown in the table below.
The majority of countries reported enhanced case-based 
data for both hepatitis B and C. Around two thirds of the 
countries who reported data in 2011 used the new case 
definitions for both diseases. The classification of cases 
into disease status was problematic for many countries 
and was a particular issue for hepatitis C, which resulted 
many cases being classified as unknown. The problem 
with the StageHEP criteria for hepatitis  C reflects the 
general difficulty in defining hepatitis C, especially acute 
hepatitis C, which is widely recognised in the published 
medical literature [5–8]. Although countries had some 
difficulty adapting their data to the new case definitions 
and classifying their cases by stage of infection, this first 
data collection still represents an important step towards 
harmonising and improving the surveillance of hepatitis B 
and C across Europe. 
Whilst many countries were able to use the revised hepa-
titis B case definition, other countries provided data using 
their own national case definition or one of the previous 
EU case definitions that did not capture chronic cases. 
Differences in case definitions between countries were 
less problematic for hepatitis C, as the previous EU case 
definition and other national case definitions permit the 
capture of both acute and chronic data. This heterogeneity 
in the data reported pose a challenge to the interpretation 
of data across countries, but should improve as more coun-
tries adapt their data to the new case definitions and get 
more experience in differentiating data as acute or chronic. 
Across all countries, more cases of hepatitis C than hepa-
titis B are reported with numbers of cases of hepatitis C 
roughly double those of hepatitis B. In most countries, the 
overall figures for both infections are driven by the large 
numbers of chronic and unknown cases. For hepatitis C, 
many of the cases are classified as ‘unknown’ but these are 
likely to be chronic infections on account of the difficulties 
in diagnosing acute disease. 
For hepatitis  B, the figures suggest a decrease in acute 
cases and a rise in newly reported chronic infections and 
the former could be explained by the availability of vaccina-
tion programmes [9]. A fall in the prevalence of HBsAg has 
been noted in many countries in Central Europe, Central 
Sub-Saharan Africa, Central America and South East Asia 
and this is considered most likely to reflect the effective 
implementation of vaccination programmes in these coun-
tries [10]. The rise in chronic cases may be due to increased 
diagnostic testing but another explanation for this rise, 
and for the variation in chronic cases between countries, 
is the difference in migration patterns between countries. 
Whilst the decrease of acute cases is reassuring, with such 
large and possibly rising numbers of chronic hepatitis B 
cases in many countries there is no room for complacency 
in national prevention and control programmes. The large 
number of chronic cases poses a burden to health care in 
terms of the associated burden of disease from cirrhosis 
and cancer and the related treatment costs.
For hepatitis C, there are no obvious trends over the period 
in either acute or chronic infections, although it is possible 
that the difficulties in defining the data in many countries 
may have masked any such trends. There is no vaccine 
commercially available to prevent hepatitis C and acute 
infections are particularly difficult to identify clinically 
and diagnose serologically. As chronic infection for both 
diseases is generally asymptomatic until a late stage, the 
numbers of chronic cases for both diseases are likely to be 
strongly related to screening programmes and diagnostic 
testing in countries. Indeed, some of the countries with the 
greatest reported burden, e.g. UK, are the ones with the 
most comprehensive screening and diagnostic testing of 
risk groups. Further epidemiological work to review these 
differences in more detail, reviewing the population tested 
denominator for example, would be useful to help clarify 
these differences. 
The large numbers of newly diagnosed cases of chronic 
hepatitis  B and hepatitis  C present a significant public 
health challenge to countries. Chronic infections have 
implications for the individual in terms of treatment and 
care and for the wider population in terms of the risks of 
possible transmission of infection. All countries should 
5. General discussion and conclusions
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have a comprehensive programme of prevention, care 
and treatment for these infections and those with a high 
or escalating burden of disease should consider strength-
ening these programs based on their local epidemiology. 
Although many of the enhanced epidemiological variables 
were poorly reported, the data completeness improved over 
the reporting period, however, further work is necessary 
to address this issue. The transmission and ‘migration’ 
variables provide interesting results which aid the under-
standing of the epidemiology of these two diseases. Despite 
the limitations of the ‘migration’ variables, the results 
provide an indication that imported cases play a more 
significant role in hepatitis B than hepatitis C, especially 
for chronic hepatitis B infections. 
Transmission routes for hepatitis B differed as compared 
to hepatitis  C, and for hepatitis  B, transmission routes 
varied by disease status. Indeed, mother-to-child transmis-
sion was more commonly reported for chronic hepatitis B 
cases as compared to acute cases and the data suggests 
that a large proportion of these cases are imported. The 
transmission of hepatitis B within countries is reflected in 
the most common transmission route reported for acute 
cases: heterosexual transmission, male-to-male transmis-
sion, injecting drug use, and nosocomial transmission.
For hepatitis C, the most common route of transmission 
across all stages of disease was injecting drug use. The 
second most common route of transmission overall was 
blood and blood products but the majority of these cases 
were among chronic cases reflecting transmission in coun-
tries in the past before the screening of blood and blood 
products. A worrying trend over the reporting period is the 
rise in reported MSM transmissions among acute hepatitis C 
cases which reinforces the need to strengthen prevention 
programmes across key risk groups in countries as this rise 
in cases has implications for other sexually transmitted 
infections in these groups. 
In conclusion, the first collection of enhanced surveil-
lance data for hepatitis B and C across Europe highlights 
a significant burden of disease associated with chronic 
infections for both diseases. The data suggest that acute 
infections are declining across many countries for hepa-
titis B, whilst for hepatitis C the challenges in classifying 
cases by disease status significantly limit any conclusions 
that can be drawn regarding acute cases. For both hepa-
titis B and C, the number of chronic cases reported from 
countries that are able to provide this information indicates 
a high burden of disease. This burden of disease related 
to chronic infection is considerably greater for hepatitis C 
than for hepatitis B. 
The comparability of data across countries is impaired 
by differences in surveillance systems. The difficulty in 
some countries in classifying cases by disease status is 
one of the most problematic differences to account for 
between countries. When all these differences are taken 
into account, there is still great variation between countries 
in their reported cases and these differences are greater 
for chronic cases than acute cases. For chronic infec-
tions, this variation reflects the different testing practices 
between countries as well as differences in the underlying 
local epidemiology, but further research is necessary to 
explore this variation. 
Enhanced surveillance of hepatitis B and C across Europe is 
essential to provide the information necessary to monitor 
the distribution of disease and to evaluate the public 
health response to prevent and control the transmission of 
infections. In order to achieve this aim, countries in Europe 
need to work towards providing high quality surveillance 
data using standard case definitions. 
35
Hepatitis B and C surveillance in Europe 2006–2011SURVEILLANCE REPORT
1. European Centre for Disease Prevention and Control. Surveillance and prevention of hepatitis B and C in Europe. Stockholm: ECDC; 2010.
2. Rantala M, van de Laar M. Surveillance and epidemiology of hepatitis B and C in Europe – a review. Eurosurveillance 2008; 13(21): 18880.
3. Chang M H. Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations. J Clin Virol. 2006. 36: 
S1:S45–50.
4. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infec-
tion. AIDS, 2010. 24(12): 1799–812.
5. Irving WL, Salmon D, Boucher C, Hoepelman IM. Acute hepatitis C virus infection. Euro Surveill, 2008. 13(21): 18879.
6. Gaudy-Graffin C,Goudeau A, Barin F, DuBois F, LeSage G, Kousignan I et al. Use of an Anti-Hepatitis C Virus (HCV) IgG Avidity Assay To Identify Recent 
HCV Infection. J. Clin. Microbiol. 2010, 48(9):3281.
7. Brant, LJ, Ramsay ME, Balogun MA, Boxall E, Hale A, Hurelle M, et al. Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and 
high-risk English populations. J Viral Hepat, 2008. 15(12): 871–7.
8. Irving WL, and Brown RJ. Acute hepatitis C virus infection: a dynamic-and challenging-concept. J Infect Dis, 2010. 202(12): 1765–7.
9. The Health Protection Surveillance Centre European Centre for Disease Control VENICE II Project. Hepatitis B Vaccination in Europe November 2008–
March 2009. http://venice.cineca.org/Report_Hepatitis_B_Vaccination.pdf (accessed 06.02.2013)
10. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and 
endemicity. Vaccine, 2012 (12) 2212–9.
References

37
Hepatitis B and C surveillance in Europe 2006–2011SURVEILLANCE REPORT
Annexes
38
SURVEILLANCE REPORTHepatitis B and C surveillance in Europe 2006–2011
Hepatitis B (hepatitis B virus)
Clinical Criteria
Not relevant for surveillance purposes 
Laboratory criteria
Positive results of at least one or more of the following 
tests or combination of tests:
•	 IgM	hepatitis	B	core	antibody	(anti-HBc	IgM)
•	 Hepatitis	B	surface	antigen	(HBsAg)
•	 Hepatitis	B	e	antigen	(HBeAg)
•	 Hepatitis	B	nucleic	acid	(HBV-DNA)
Epidemiological criteria
Not relevant for surveillance purposes 
Case classification
A. Possible case
NA
B. Probable case
NA
C. Confirmed case
Any person meeting the laboratory criteria
Comments/notes 
NOTE: The following combination of laboratory tests shall 
not be included or reported:
•	 Resolved	hepatitis	 –	Hepatitis	 B	 total	 core	 antibody	
(anti-HBc) positive and hepatitis B surface antibody 
(anti-HBs) positive
•	 Immunity	following	vaccination	–	Hepatitis	B	total	core	
antibody (anti-HBc) negative and hepatitis B surface 
antibody (anti-HBs) positive 
•	 Anti-HBc	IgG	positivity	only
NOTE: Elevated levels of IgM in some chronic cases may 
result in misclassification which could overestimate the 
number of acute cases
Hepatitis C (hepatitis C virus)
Clinical criteria
Not relevant for surveillance purposes 
Laboratory criteria
At least one of the following three:
•	 Detection	of	hepatitis	C	virus	nucleic	acid	(HCV	RNA)
•	 Detection	of	hepatitis	C	virus	specific	antigen	(HCVcore)
•	 Hepatitis	C	virus	specific	antibody	(anti-HCV)	response	
confirmed by a confirmatory (e.g. immunoblot) antibody 
test in persons older than 18 months without evidence 
of resolved infection
Epidemiological criteria
Not relevant for surveillance purposes 
Case classification
A. Possible case 
NA
B. Probable case
NA
C. Confirmed case
Any person meeting the laboratory criteria 
Comments/Notes 
NOTE: The following combination of lab tests shall not be 
included or reported: 
Resolved infection: Detection of hepatitis C virus antibody 
and no detection of hepatitis C virus nucleic acid (HCV 
RNA negative result) or hepatitis C virus core antigen 
(HCV‐core negative result) in serum/plasmaSource: 
2012/506/EU: Commission Implementing Decision of 8 
August 2012 amending Decision 2002/253/EC laying down 
case definitions for reporting communicable diseases to 
the Community network under Decision No 2119/98/EC of 
the European Parliament and of the Council (notified under 
document C(2012) 5538)
Annex 1. Case definitions for hepatitis B and C
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Disease and code Description
Hepatitis B
Acute
Detection of IgM antigen specific antibody (anti-HBc IgM) 
     or
Detection of hepatitis surface antigen (HBsAg) and previous negative HBV markers less than 6 months ago
     or
Detection of hepatitis B nucleic acid (HBV-DNA) and previous negative HBV markers less than six months ago
Any of the above with or without symptoms and signs (e.g. jaundice, elevated serum aminotransferase levels, fatigue, abdominal pain, loss of appetite, 
intermittent nausea, vomiting, fever)
Chronic
Detection of HBsAg or HBeAg or HBV-DNA 
     and
No detection of anti-HBc IgM (negative result)
     or
Detection of HBsAg or HBeAg or HBV-DNA on two occasions that are six months apart*
Unknown Any newly diagnosed case which cannot be classified according the above description of acute or chronic infection
Hepatitis C
Acute
Recent HCV seroconversion (prior negative test for hepatitis C in last 12 months)
     or
Detection of hepatitis C virus nucleic acid (HCV RNA) or hepatitis C virus core antigen (HCV-core) in serum/plasma and no detection of hepatitis C virus 
antibody (negative result)
Chronic Detection of hepatitis C virus nucleic acid (HCV RNA) or hepatitis C core antigen (HCV-core) in serum/plasma in two samples taken at least 12 months apart*
Unknown Any newly diagnosed case which cannot be classified according the above description of acute or chronic infection
*In the event that the case was not notified the first time
Annex 2. Implementation of case definitions 
with the StageHEP variable
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Annex 3. Enhanced set of variables for 
hepatitis B and C surveillance
Type and variable Name Mandatory Hepatitis B Hepatitis C
Core set
RecordId Yes √ √
RecordType Yes √ √
RecordTypeVersion No √ √
Subject Yes √ √
DataSource Yes √ √
ReportingCountry Yes √ √
DateUsedForStatistics Yes √ √
Status No √ √
DateOfNotification No √ √
DateOfDiagnosis Yes √ √
PlaceOfResidence No √ √
PlaceOfNotification No √ √
Age (years) Yes √ √
Gender Yes √ √
DateOfOnset No √ √
Outcome No √ √
Classification Yes √ √
Disease-specific
StageHEP Yes √ √
ResultHBeAg No √ NA
TestingLocation No √ √
CountryOfBirth No √ √
CountryOfNationality No √ √
Imported No √ √
ProbableCountryOfInfection No √ √
Transmission Yes √ √
SexWorker No √ √
HealthCareWorker No √ √
HIVStatus No √ √
HBVStatus No NA √
HCVStatus No √ NA
VaccStatus No √ NA
Complications No √ √
Genotype No √ √
NA: not applicable
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Annex 4. Completeness of reporting
Type and variable Name
Overall 2006 2011
Proportion 
complete – all 
years (%)
Proportion 
complete – 
2006–2010 
(%)
Proportion 
complete – 
2011 (%)
Number of 
countries
Maximum 
complete (%)
Minimum 
complete (%)
Number of 
countries
Maximum 
complete (%)
Minimum 
complete (%)
Hepatitis B
Age 99.4 99.3 99.9 16 100.0 30.2 27 100.0 82.9
Complications 3.8 4.0 3.0 2 87.8 30.2 5 100.0 3.8
Country of birth 15.6 14.7 19.1 6 73.3 2.0 11 100.0 7.7
Country of nationality 6.8 6.8 6.8 4 100.0 2.6 10 100.0 7.7
Gender 97.0 96.8 98.0 16 100.0 30.2 27 100.0 91.7
Genotype 0.0 0.0 0.0 1 0.9 0.9 2 0.4 0.1
HBeAg Status 12.4 12.9 10.4 3 73.3 29.0 12 90.1 0.1
HCV status 5.7 6.4 3.1 4 84.6 0.2 9 100.0 1.9
Health care worker 14.9 13.4 21.0 11 100.0 0.1 18 100.0 0.0
HIV status 4.4 4.5 4.1 2 100.0 2.3 6 100.0 0.1
Imported 38.8 39.5 39.1 12 100.0 1.1 18 100.0 0.1
Outcome 30.6 30.2 30.4 12 100.0 1.8 22 100.0 0.7
Probable country of infection 23.2 23.9 20.2 11 100.0 0.7 15 82.4 0.1
Sex worker 5.1 3.7 10.9 3 100.0 12.1 9 100.0 0.1
StageHEP 77.8 75.2 88.4 14 100.0 67.2 24 100.0 3.8
Testing location 17.6 19.0 11.7 5 89.5 1.8 9 100.0 1.4
Transmission 17.8 17.8 17.8 13 73.6 3.7 20 86.4 6.3
Vaccination status 22.3 21.9 23.6 10 92.6 5.1 18 99.7 4.2
Hepatitis C
Age 99.0 98.8 100.0 15 100.0 10.3 24 100.0 94.4
Complications 5.8 5.8 5.8 2 100.0 0.5 4 100.0 0.6
Country of birth 14.5 14.5 14.4 5 93.0 4.2 8 99.3 15.5
Country of nationality 5.9 5.7 6.6 4 100.0 3.7 8 100.0 79.6
Gender 97.8 97.6 98.7 15 100.0 10.3 24 100.0 97.6
Genotype 2.4 2.4 2.4 2 7.5 0.9 6 14.7 0.1
HBV status 4.1 4.8 0.6 4 83.0 0.8 8 82.9 0.5
Health care worker 7.4 7.2 8.0 8 100.0 3.5 13 100.0 0.2
HIV status 4.9 5.7 1.4 2 100.0 0.2 7 100.0 0.4
Imported 45.1 46.2 40.5 11 100.0 1.0 17 100.0 2.7
Outcome 40.5 40.8 35.1 12 100.0 0.8 24 100.0 0.1
Probable country of infection 13.3 14.5 7.6 9 100.0 2.0 13 100.0 0.2
Sex worker 1.3 1.3 1.5 2 100.0 100.0 6 100.0 0.5
StageHEP 10.8 10.2 13.3 8 100.0 0.6 13 100.0 4.4
Testing Location 19.9 20.5 16.1 5 85.5 10.1 9 100.0 0.1
Transmission 31.9 32.6 28.9 12 86.8 3.8 19 83.3 10.1
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Table A5: Proportiona (%) of cases of hepatitis B by disease status and transmission category in EU and EEA countriesb 
in 2011
Countries
Disease status
Blood and blood 
products
Haemo-dialysis
Heterosexual 
transmission
Household
Injecting drug use
M
SM
M
other to child 
transmission
on occupational
Nosocomial
Other
Needlestick & 
other occupational 
exposure
Sexual 
transmission (not 
specified)
Organ and tissues
Unknown
Austria
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Chronic 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Cyprus
Acute
Chronic
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Czech Republic
Acute 0.0 0.0 0.0 0.0 28.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 71.7
Chronic
Unknown
Denmark
Acute 0.0 0.0 58.8 5.9 5.9 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.5
Chronic 0.0 0.0 3.7 1.6 5.3 1.6 72.0 0.4 3.3 0.4 0.0 0.0 0.0 11.5
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Estonia
Acute 0.0 0.0 13.3 0.0 33.3 0.0 0.0 0.0 6.7 0.0 0.0 0.0 0.0 46.7
Chronic 0.0 0.0 14.8 0.0 33.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 51.9
Unknown
Finland
 
Acute 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 37.5 0.0 58.3
Chronic 0.9 0.0 0.0 0.0 0.4 0.0 4.0 0.0 0.0 0.0 0.0 5.8 0.0 88.8
Unknown
Francec
Acute 0.0 0.0 5.9 4.0 1.0 8.9 1.0 1.0 5.0 7.9 3.0 1.0 0.0 61.4
Chronic
Unknown
Germany
Acute 0.1 0.7 3.8 2.9 1.7 2.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 88.2
Chronic
Unknown 0.0 0.0 0.0 1.0 2.9 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 94.3
Greece
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Chronic
Unknown
Hungary
Acute 0.0 0.0 0.0 1.5 7.7 0.0 0.0 1.5 0.0 0.0 0.0 15.4 0.0 73.8
Chronic
Unknown
Iceland
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Chronic
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Ireland
Acute 0.0 0.0 23.3 0.0 0.0 23.3 0.0 2.3 2.3 4.7 0.0 27.9 0.0 16.3
Chronic 1.1 0.0 0.9 0.4 0.2 2.0 0.7 0.7 0.4 30.9 0.0 2.0 0.0 60.7
Unknown 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 9.5 0.0 4.8 0.0 81.0
Italy
Acute 0.5 0.2 16.6 7.2 0.5 4.1 0.0 14.9 15.2 11.1 0.0 2.7 0.0 27.0
Chronic
Unknown
Latvia
Acute 1.9 0.0 0.0 3.7 18.5 0.0 0.0 5.6 14.8 0.0 0.0 31.5 0.0 24.1
Chronic 3.5 0.0 0.0 0.0 1.8 0.0 0.0 1.8 14.0 0.0 0.0 19.3 0.0 59.6
Unknown 0.6 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.6 7.9 0.0 90.4
Lithuania
Acute 0.0 0.0 28.3 0.0 13.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 58.3
Chronic
Unknown
Luxembourg
Acute
Chronic
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.0 0.0 0.0 0.0 0.0 0.0 93.8
Malta
Acute 0.0 0.0 33.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 66.7
Chronic 3.1 0.0 6.3 0.0 0.0 0.0 3.1 0.0 0.0 3.1 0.0 0.0 0.0 84.4
Unknown
Netherlands
Acute 0.0 0.0 31.8 0.0 0.0 31.2 0.0 0.0 0.0 0.0 0.6 0.6 0.0 35.7
Chronic 0.0 0.0 3.0 0.0 0.2 1.8 59.8 0.0 0.0 0.0 0.1 0.0 0.0 35.2
Unknown 0.0 0.0 10.5 0.0 0.0 10.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 78.9
Norway
Acute 0.0 0.0 39.3 0.0 32.1 7.1 0.0 1.8 1.8 0.0 0.0 3.6 0.0 14.3
Chronic 1.4 0.0 0.1 0.0 3.0 0.4 7.4 0.4 0.1 0.0 0.0 5.7 0.0 81.5
Unknown
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Countries
Disease status
Blood and blood 
products
Haemo-dialysis
Heterosexual 
transmission
Household
Injecting drug use
M
SM
M
other to child 
transmission
on occupational
Nosocomial
Other
Needlestick & 
other occupational 
exposure
Sexual 
transmission (not 
specified)
Organ and tissues
Unknown
Poland
Acute 1.9 2.9 1.0 6.7 6.7 1.0 0.0 0.0 49.0 1.0 0.0 4.8 0.0 25.0
Chronic
Unknown
Portugal
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Chronic
Unknown 0.0 0.0 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.0 84.0
Romania
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.0 0.0 0.0 8.5 0.0 69.5
Chronic 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 0.0
Unknown
Slovakia
Acute 1.1 0.0 6.5 2.2 7.5 0.0 0.0 2.2 37.6 0.0 0.0 0.0 0.0 43.0
Chronic 5.3 0.0 1.3 2.6 7.9 0.0 0.0 13.2 23.7 0.0 1.3 0.0 0.0 44.7
Unknown
Slovenia
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Chronic 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Unknown
Sweden
Acute 0.0 0.0 44.9 3.4 20.2 9.0 1.1 2.2 2.2 2.2 0.0 0.0 0.0 14.6
Chronic 1.8 0.0 3.9 0.5 0.9 0.1 8.7 0.2 1.4 2.8 0.3 0.0 0.0 79.5
Unknown 0.0 0.0 3.2 0.0 0.0 0.0 6.3 0.0 1.6 0.0 3.2 0.0 0.0 85.7
United Kingdomd
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Chronic 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Source: Country reports (Countries included if able to provide data on transmission)
a Calculated as % of total number of cases not recorded as unknown.
b Due to the significant differences in surveillance systems between countries and over time, comparisons between individual Member States and over time should 
be interpreted with caution.
c Under-reporting was estimated to be 85% in France for acute hepatitis B cases in 2010.
d Data excludes Scotland
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Table A6: Proportiona (%) of cases of hepatitis C by disease status and transmission category in EU and EEA countriesb 
in 2011
Countries
Disease status
Blood and blood 
products
Haemo-dialysis
Heterosexual 
transmission
Household
Injecting drug use
M
SM
M
other to child 
transmission
on occupational
Nosocomial
Other
Needlestick & 
other occupational 
exposure
Sexual 
transmission (not 
specified)
Organ and tissues
Unknown
Austria
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Chronic 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Cyprus
Acute               
Chronic               
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Czech Republic
Acute               
Chronic               
Unknown 0.0 0.0 0.0 0.0 62.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 37.7
Denmark
Acute 0.0 0.0 0.0 0.0 28.6 57.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.3
Chronic 0.0 0.0 3.6 0.7 68.9 0.0 0.7 1.4 6.4 0.4 0.4 0.0 0.0 17.5
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Estonia
Acute 0.0 0.0 0.0 0.0 25.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 75.0
Chronic 0.0 0.0 12.8 0.0 36.2 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 49.5
Unknown               
France
Acute               
Chronic               
Unknown               
Finland
Acute               
Chronic               
Unknown 0.6 0.0 0.0 0.0 54.2 0.3 1.0 0.0 0.0 0.0 0.0 7.5 0.0 36.5
Germany
Acute               
Chronic               
Unknown 7.8 0.4 0.0 0.0 22.4 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 68.3
Greece
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Chronic 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Hungary
Acute 0.0 0.0 0.0 0.0 35.0 0.0 0.0 5.0 0.0 0.0 0.0 5.0 0.0 55.0
Chronic               
Unknown               
Iceland
Acute               
Chronic               
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Ireland
Acute 0.0 9.1 0.0 0.0 27.3 0.0 0.0 9.1 0.0 9.1 0.0 27.3 0.0 18.2
Chronic 12.8 0.0 0.0 0.0 46.8 0.0 2.1 0.0 1.1 16.0 1.1 4.3 0.0 16.0
Unknown 0.8 0.0 0.0 0.0 50.6 0.0 0.5 0.4 0.3 2.7 0.3 1.6 0.0 43.2
Italy
Acute 0.0 1.0 1.9 11.4 23.8 1.0 0.0 8.6 30.5 2.9 0.0 0.0 0.0 19.0
Chronic               
Unknown               
Latvia
Acute               
Chronic               
Unknown 6.4 0.8 0.0 0.3 16.1 0.1 0.4 2.7 3.5 0.0 0.8 11.1 0.0 61.4
Lithuania
Acute 0.0 0.0 20.9 0.0 9.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 69.8
Chronic               
Unknown               
Luxembourg
Acute               
Chronic               
Unknown 4.1 0.0 0.0 0.0 64.9 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 29.7
Malta
Acute               
Chronic               
Unknown 11.1 0.0 0.0 0.0 72.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.7
Netherlands
Acute 0.0 0.0 4.6 0.0 1.5 67.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.2
Chronic               
Unknown               
Norway
Acute               
Chronic               
Unknown 2.2 0.0 0.1 0.0 37.0 0.1 0.4 0.4 0.0 0.0 0.0 2.6 0.0 57.7
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Countries
Disease status
Blood and blood 
products
Haemo-dialysis
Heterosexual 
transmission
Household
Injecting drug use
M
SM
M
other to child 
transmission
on occupational
Nosocomial
Other
Needlestick & 
other occupational 
exposure
Sexual 
transmission (not 
specified)
Organ and tissues
Unknown
Poland
Acute      `          
Chronic               
Unknown               
Portugal
Acute 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Chronic               
Unknown 0.0 0.0 0.0 0.0 60.5 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.0 34.9
Romania
Acute               
Chronic               
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.3 0.0 0.0 2.5 0.0 51.3
Slovakia
Acute 4.8 0.0 4.8 0.0 57.1 0.0 0.0 0.0 9.5 0.0 0.0 0.0 0.0 23.8
Chronic 5.8 0.0 0.0 0.4 40.7 0.0 0.0 6.9 16.0 0.0 1.1 1.1 0.0 28.0
Unknown               
Slovenia
Acute 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Chronic 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Unknown               
Sweden
Acute               
Chronic               
Unknown 4.8 0.0 4.3 0.2 46.9 0.6 0.3 1.6 1.4 1.2 0.4 0.0 0.0 39.9
United Kingdom
Acute               
Chronic 0.6 0.0 0.0 0.0 47.8 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 49.9
Unknown 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 95.5
Source: Country reports (Countries included if able to provide data on transmission)
a Calculated as % of total number of cases not recorded as unknown.
b Due to the significant differences in surveillance systems between countries and over time, comparisons between individual Member States and over time should 
be interpreted with caution.
50
SURVEILLANCE REPORTHepatitis B and C surveillance in Europe 2006–2011
Ta
bl
e 
A7
: P
ro
po
rt
io
na
 (%
) o
f c
as
es
 o
f h
ep
at
iti
s 
B 
by
 tr
an
sm
is
si
on
 c
at
eg
or
y 
in
 E
U 
an
d 
EE
A 
co
un
tr
ie
s 
be
tw
ee
n 
20
06
 a
nd
 2
01
1
Tr
an
sm
iss
io
n
20
06
20
07
20
08
20
09
20
10
20
11
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Bl
oo
d 
an
d 
bl
oo
d 
pr
od
uc
ts
0.
5
4.0
1.2
0.4
4.
3
1.2
0.1
4.
5
3.0
0.4
4.
5
3.6
0.
2
2.4
5.
3
0.6
2.4
2.
0
Ha
em
od
ial
ys
is
0.
8
0.0
1.8
0.4
0.0
4.
3
0.
3
0.0
0.7
0.4
0.1
0.0
0.
3
0.1
0.0
0.
8
0.0
0.0
He
te
ro
se
xu
al 
tra
ns
m
iss
io
n
31
.1
9.9
4.1
27
.1
8.1
3.9
27
.4
6.9
5.0
26
.7
9.9
1.8
27
.7
6.7
4.7
23
.4
6.1
18
.4
Ho
us
eh
ol
d
7.5
4.6
5.
3
6.
8
2.9
7.8
5.6
2.
6
7.0
7.1
2.
6
6.
5
5.6
1.6
7.6
6.
3
0.
8
2.
0
In
je
ct
in
g 
dr
ug
 u
se
r
18
.8
13
.1
17
.1
23
.6
10
.9
20
.8
25
.1
10
.3
19
.7
18
.9
6.1
21
.4
17
.0
4.6
20
.5
13
.4
3.
5
8.
2
M
en
 w
ho
 h
av
e s
ex
 w
ith
 m
en
/ h
om
os
ex
ua
l o
r b
ise
xu
al 
m
ale
8.
5
2.1
2.4
8.
0
2.
0
0.4
9.1
1.6
1.0
12
.8
2.
5
3.0
12
.9
2.
5
3.
5
10
.3
2.4
12
.2
M
ot
he
r-t
o-
ch
ild
 tr
an
sm
iss
io
n
1.0
41
.2
6.
5
0.
8
34
.5
1.2
0.4
27
.4
2.
0
0.
2
40
.0
1.8
0.
5
63
.5
2.9
0.4
67
.3
10
.2
No
n-
oc
cu
pa
tio
n
7.9
0.9
2.4
8.
8
0.
3
3.9
8.
6
1.1
4.
3
9.6
0.
8
2.4
6.1
0.6
8.
2
6.
6
1.1
0.0
No
so
co
m
ial
 (i
nc
lu
de
s h
os
pi
ta
l, n
ur
sin
g 
ho
m
e, 
ps
yc
hi
at
ric
 in
st
itu
tio
ns
)
11
.7
3.0
29
.4
12
.5
4.4
20
.8
10
.2
4.
3
19
.7
9.9
4.7
16
.1
16
.1
1.8
16
.4
23
.2
2.9
2.
0
Ot
he
r
6.
5
14
.1
2.4
6.7
27
.4
5.
5
9.1
37
.1
10
.4
9.0
22
.4
0.6
9.4
12
.0
1.2
5.
3
9.3
4.1
Ne
ed
le
-st
ick
 an
d 
ot
he
r o
cc
up
at
io
na
l e
xp
os
ur
e (
in
clu
de
s h
ea
lth
ca
re
 w
or
ke
rs 
an
d 
ne
ed
le
 st
ick
 in
ju
rie
s)
0.6
3.
3
1.8
0.4
3.
5
2.7
0.
2
1.1
4.0
0.
3
0.4
0.6
0.
5
0.
3
0.6
0.4
0.
3
6.1
Se
xu
al 
tra
ns
m
iss
io
n 
(n
ot
 sp
ec
ifi
ed
)
5.1
3.9
25
.9
4.
3
1.8
27
.5
4.0
3.1
23
.1
4.6
6.0
42
.3
3.
8
3.
8
29
.2
9.3
3.9
34
.7
Or
ga
n 
an
d 
tis
su
es
0.0
0.0
0.0
0.1
0.1
0.0
To
ta
l
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
So
ur
ce
: C
ou
nt
ry
 re
po
rt
s 
(D
at
a 
in
cl
ud
ed
 fr
om
 th
e 
fo
llo
w
in
g 
co
un
tr
ie
s:
 C
ze
ch
 R
ep
ub
lic
, D
en
m
ar
k,
 E
st
on
ia
, F
in
la
nd
, F
ra
nc
e*
*, 
G
er
m
an
y,
 H
un
ga
ry
, I
ce
la
nd
, I
re
la
nd
, I
ta
ly
, L
at
vi
a,
 L
ith
ua
ni
a,
 L
ux
em
bo
ur
g,
 M
al
ta
, 
N
et
he
rla
nd
s,
 N
or
w
ay
, P
ol
an
d,
 P
or
tu
ga
l, 
Ro
m
an
ia
, S
lo
va
ki
a,
 S
w
ed
en
, U
ni
te
d 
Ki
ng
do
m
 (e
xc
lu
di
ng
 S
co
tla
nd
)).
a  
Ca
lc
ul
at
ed
 a
s 
%
 o
f t
ot
al
 n
um
be
r o
f c
as
es
 n
ot
 re
co
rd
ed
 a
s 
un
kn
ow
n.
Ta
bl
e 
A8
: P
ro
po
rt
io
na
 (%
) o
f c
as
es
 o
f h
ep
at
iti
s 
C 
by
 tr
an
sm
is
si
on
 c
at
eg
or
y 
in
 E
U 
an
d 
EE
A 
co
un
tr
ie
s 
be
tw
ee
n 
20
06
 a
nd
 2
01
1
Tr
an
sm
iss
io
n
20
06
20
07
20
08
20
09
20
10
20
11
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Acute
Chronic
Unknown
Bl
oo
d 
an
d 
bl
oo
d 
pr
od
uc
ts
0.0
1.7
14
.6
1.2
1.4
12
.2
0.0
1.8
11
.7
0.0
1.4
8.9
1.3
1.4
9.4
0.
5
2.7
9.4
Ha
em
od
ial
ys
is
0.0
0.0
0.
8
0.0
0.0
0.
5
0.0
0.0
0.4
0.7
0.0
0.
3
0.0
0.0
0.6
1.0
0.0
0.4
He
te
ro
se
xu
al 
tra
ns
m
iss
io
n
8.7
1.2
1.4
5.
2
1.0
1.2
3.7
0.7
1.1
6.
5
1.2
1.4
1.9
1.2
1.1
7.5
2.
5
1.4
Ho
us
eh
ol
d
3.6
0.0
0.1
5.
2
0.1
0.
3
8.
8
0.1
0.1
8.
6
0.0
0.
2
4.
5
0.1
0.1
6.0
0.
2
0.1
In
je
ct
in
g 
dr
ug
 u
se
r
40
.6
81
.5
77
.7
36
.4
77
.2
76
.5
35
.3
73
.7
76
.7
32
.4
79
.5
78
.6
31
.6
82
.7
77
.8
33
.3
83
.7
78
.4
M
en
 w
ho
 h
av
e s
ex
 w
ith
 m
en
/ h
om
os
ex
ua
l o
r b
ise
xu
al 
m
ale
0.7
0.
5
0.7
1.2
0.
3
0.6
2.
2
0.1
0.9
9.4
0.
2
0.9
15
.5
0.1
1.1
24
.4
0.0
1.3
M
ot
he
r-t
o-
ch
ild
 tr
an
sm
iss
io
n
0.0
0.
2
0.7
0.6
0.6
0.6
0.0
0.
3
0.6
0.0
0.4
0.6
0.0
0.4
0.
8
0.0
0.
3
0.6
No
n-
oc
cu
pa
tio
n
8.7
1.1
0.4
7.5
0.4
0.7
9.6
0.6
1.0
7.2
0.
5
1.1
6.
5
0.9
1.4
6.0
1.9
1.2
No
so
co
m
ial
 (i
nc
lu
de
s h
os
pi
ta
l, n
ur
sin
g 
ho
m
e, 
ps
yc
hi
at
ric
 in
st
itu
tio
ns
)
23
.9
2.9
1.0
31
.8
3.4
2.
5
24
.3
2.4
2.
6
23
.7
1.0
2.
5
21
.3
1.6
3.0
16
.9
4.7
1.7
Ot
he
r
8.7
10
.8
0.
2
5.8
15
.4
1.0
5.
2
20
.3
0.6
5.8
15
.8
1.4
16
.1
11
.0
0.9
2.
0
3.0
0.9
Ne
ed
le
-st
ick
 an
d 
ot
he
r o
cc
up
at
io
na
l e
xp
os
ur
e (
in
clu
de
s h
ea
lth
ca
re
 w
or
ke
rs 
an
d 
ne
ed
le
 st
ick
 in
ju
rie
s)
2.9
0.1
0.
2
1.2
0.1
0.
5
1.5
0.1
0.
3
0.0
0.0
0.
3
1.3
0.4
0.4
0.0
0.4
0.
3
Se
xu
al 
tra
ns
m
iss
io
n 
(n
ot
 sp
ec
ifi
ed
)
2.
2
0.1
2.
2
4.1
0.0
3.
5
9.6
0.0
4.0
5.8
0.1
3.9
0.0
0.
2
3.4
2.
5
0.
5
4.
3
Or
ga
n 
an
d 
tis
su
es
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
To
ta
l
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
10
0
So
ur
ce
: C
ou
nt
ry
 re
po
rt
s 
(D
at
a 
in
cl
ud
ed
 fr
om
 th
e 
fo
llo
w
in
g 
co
un
tr
ie
s:
 C
ze
ch
 R
ep
ub
lic
, D
en
m
ar
k,
 E
st
on
ia
, F
in
la
nd
, G
er
m
an
y,
 H
un
ga
ry
, I
ce
la
nd
, I
re
la
nd
, I
ta
ly
, L
at
vi
a,
 L
ith
ua
ni
a,
 M
al
ta
, N
et
he
rla
nd
s,
 N
or
w
ay
, 
Po
la
nd
, P
or
tu
ga
l, 
Ro
m
an
ia
, S
lo
va
ki
a,
 S
w
ed
en
, U
ni
te
d 
Ki
ng
do
m
). 
a  
Ca
lc
ul
at
ed
 a
s 
%
 o
f t
ot
al
 n
um
be
r o
f c
as
es
 n
ot
 re
co
rd
ed
 a
s 
un
kn
ow
n.
51
Hepatitis B and C surveillance in Europe 2006–2011SURVEILLANCE REPORT
Table A9: Number and proportion of cases of hepatitis B cases classified as ‘imported’ by disease status in EU and EEA 
countries in 2011
Country
Acute Chronic Unknown
Number of 
imported cases
Total number 
of cases 
with valid 
information
% Imported Number of imported cases
Total number 
of cases 
with valid 
information
% Imported Number of imported cases
Total number 
of cases 
with valid 
information
% Imported
Austria 0 75 0.0 27 380 7.1 1 72 1.4
Cyprus   
Czech Republic 0 191 0.0
Denmark 1 16 6.3 207 236 87.7 4 4 100.0
Estonia 1 15 6.7 0 27 0.0
Finland 9 13 69.2 122 129 94.6
Francea 10 62 16.1
Germany 0 688 0.0 0 105 0.0
Greece 0 38 0.0
Hungary 0 65 0.0
Iceland     
Ireland 13 37 35.1 117 125 93.6 2 3 66.7
Italy   
Latvia 2 54 3.7      
Lithuania 1 60 1.7
Luxembourg   
Malta 2 3 66.7 18 32 56.3
Netherlands 25 146 17.1 1201 1378 87.2 6 18 33.3
Norway 27 54 50.0 668 698 95.7
Poland 0 102 0.0
Portugal     
Romania     
Slovakia 1 93 1.1 1 76 1.3
Slovenia     
Spain 0 520 0.0
Sweden 22 86 25.6 983 1023 96.1 25 27 92.6
United Kingdomb   11 11 100.0   
Totalf 114 1798 6.3 3355 4115 81.5 38 749 5.1
a Under-reporting was estimated to be 85% in France for acute hepatitis B cases in 2010.
b Excluding Scotland.
Table A10: Number and proportion of cases of hepatitis C cases classified as ‘imported’ in EU and EEA countries in 2011
Country
Acute Chronic Unknown
Number of 
imported cases
Total number 
of cases 
with valid 
information
% Imported Number of imported cases
Total number 
of cases 
with valid 
information
% Imported Number of imported cases
Total number 
of cases 
with valid 
information
% Imported
Austria 7 71 9.9 9 151 6 0 5 0
Cyprus
Czech Republic 0 812 0.0
Denmark 2 6 33.3 58 262 22.1 4 4 100.0
Estonia 0 16 0.0 0 188 0.0
Finland 97 411 23.6
Germany 8 4902 0.2
Greece 0 11 0.0 0 6 0.0 0 1 0.0
Hungary 0 40 0.0
Iceland
Ireland 0 5 0.0 49 79 62.0 37 72 51.4
Italy
Latvia 8 1217 0.7
Lithuania 0 43 0.0
Luxembourg
Malta 3 18 16.7
Netherlands 6 55 10.9
Norway 227 1670 13.6
Poland
Portugal
Romania
Slovakia 0 21 0.0 25 275 9.1
Slovenia
Spain
Sweden 307 1444 21.3
United Kingdom 153 319 48.0 6 7 85.7
Total 15 268 5.6 294 1280 23.0 697 10563 6.6
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Table A11: Differences between reporting country and the country of birth or nationality of hepatitis B cases, in EU/EEA 
countries, 2011
Country
Acute Chronic Unknown
Proportion of cases 
where reporting country 
≠ Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
= Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
≠ Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
= Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
≠ Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
= Country of birth/
nationality (%)
Austria 0.0 0.0 0.0 0.0 0.0 0.0
Cyprus 60.0 40.0
Czech Republic 0.0 100.0
Germany 100.0 0.0 100.0 0.0
Denmark 11.8 88.2 81.9 17.3 50.0 50.0
Estonia 0.0 100.0 0.0 100.0
Finland 16.7 70.8 64.7 12.5
Francea 5.9 23.8
Greece 100.0 0.0
Hungary 1.5 98.5
Ireland 27.9 65.1 34.4 3.3 28.6 4.8
Iceland 0.0 0.0 0.0 0.0
Italy 18.1 81.2
Lithuania 0.0 100.0
Latvia 0.0 0.0 0.0 0.0 0.0 0.0
Luxembourg 100.0 0.0
Malta 33.3 66.7 71.9 28.1
Netherlands 12.3 83.8 83.5 11.4 26.3 34.2
Norway 0.0 92.9 0.0 5.0
Poland 2.9 97.1
Portugal 0.0 0.0 4.0 4.0
Romania 0.0 0.0 0.0 0.0 0.0
Slovenia 0.0 0.0 0.0 0.0 12.7 1.6
Slovakia 100.0 0.0 100.0 0.0
Spain 0.0 0.0
Sweden 20.2 34.8 59.9 2.5 12.7 1.6
United Kingdom 0.0 0.0 0.0 0.0 0.0 0.0
Total 35.4 26.9 22.0 3.1 7.8 1.1
Source: Country reports. Cases were excluded from the analysis if information on country of birth or country of nationality were missing.
a Under-reporting was estimated to be 85% in France for acute hepatitis B cases in 2010.
Table A12: Differences between reporting country and the country of birth or nationality of hepatitis C cases, in EU/EEA 
countries, 2011
Country
Acute Chronic Unknown
Proportion of cases 
where reporting country 
≠ Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
= Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
≠ Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
= Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
≠ Country of birth/
nationality (%)
Proportion of cases 
where reporting country 
= Country of birth/
nationality (%)
Austria 0.0 0.0 0.0 0.0 0.0 0.0
Cyprus 68.5 11.1
Czech Republic 0.0 100.0
Germany 100.0 0.0
Denmark 14.3 85.7 21.1 78.9 25.0 75.0
Estonia 0.0 100.0 0.0 100.0
Finland 14.4 81.4
Greece 100.0 0.0 100.0 0.0 100.0 0.0
Hungary 0.0 100.0
Ireland 27.3 63.6 46.8 40.4 4.8 4.1
Iceland 0.0 0.0
Italy 9.5 90.5
Lithuania 0.0 100.0
Latvia 0.0 0.0
Luxembourg 100.0 0.0
Malta 22.2 77.8
Netherlands 16.9 66.2
Norway 0.0 75.2
Poland
Portugal 0.0 0.0 0.0 0.0
Romania 0.0 0.0
Slovenia 0.0 0.0
Slovakia 0.0 0.0 100.0 0.0
Spain 100.0 0.0
Sweden 17.8 37.7
United Kingdom 0.0 0.0 0.0 0.0
Total 10.5 45.9 12.1 14.1 26.4 12.5
Source: Country reports. Cases were excluded from the analysis if information on country of birth or country of nationality were missing.
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Table A13: Number of deaths of hepatitis B cases in EU 
and EEA countries in 2011a
Country Number of cases with valid data on outcome Number of deaths
Austria 574 5
Cyprus 10 0
Czech Republic 191 1
Denmark 70 1
Estonia 42 0
Finland 0 0
Franceb 101 0
Germany 791 7
Greece 38 1
Hungary 65 4
Iceland 0 0
Ireland 34 0
Italy 399 6
Latvia 289 2
Lithuania 30 1
Luxembourg 0 0
Malta 35 2
Netherlands 1695 5
Norway 23 2
Poland 104 3
Portugal 23 2
Romania 411 3
Slovakia 169 3
Slovenia 69 1
Spain 0 0
Sweden 9 9
United Kingdom 0 0
Total 5172 58
a Bulgaria and Poland excluded as data submitted in aggregate format 
which was not suitable for analysis
b Under-reporting was estimated to be 85% in France for acute hepatitis B 
cases in 2010.
Table A14: Number of deaths of hepatitis C cases in EU 
and EEA countries in 2011a
Country Number of cases with valid data on outcome Number of deaths
Austria 789 1
Cyprus 54 0
Czech Republic 812 2
Denmark 48 5
Estonia 204 0
Finland 0 0
Germany 4810 3
Greece 18 1
Hungary 40 1
Iceland 0 0
Ireland 14 0
Italy 103 1
Latvia 1217 0
Lithuania 12 0
Luxembourg 0 0
Malta 18 0
Netherlands 65 0
Norway 1 0
Portugal 42 0
Romania 80 2
Slovakia 296 0
Slovenia 95 1
Sweden 74 4
United Kingdom 1696 55
Total 10488 76
a Bulgaria and Poland excluded as data submitted in aggregate format 
which was not suitable for analysis
Table A15: Number of reported hepatitis C cases per 100 000 population by disease status and gender in EU/EEA 
countries, 2006–2011
Year All cases Acute cases Chronic cases UnknownMale Female Male Female Male Female Male Female
2006 12.2 6.5 0.5 0.4 3.9 1.8 12.2 6.6
2007 10.7 5.7 0.8 0.7 3.8 1.9 13.7 7.4
2008 11.7 6.2 0.7 0.4 3.7 1.8 15.5 8.4
2009 11.6 6.1 0.8 0.4 4.3 1.9 14.2 7.4
2010 10.9 5.6 2.1 1.3 4.4 1.9 13.1 6.6
2011 10.7 5.4 2.3 1.3 5.6 2.7 14.9 7.5
Source: Country reports: Austria, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the 
Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden, United Kingdom.
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